<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>regeneron_10q.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">

<P align=center><FONT face=serif size=2>UNITED STATES <BR></FONT><FONT face=serif size=2>SECURITIES AND EXCHANGE COMMISSION <BR>Washington, D.C.
20549</FONT></P>
<P align=center><B><FONT face=serif size=2>Form 10-Q</FONT></B></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3><FONT face=serif size=2>(Mark
      One)</FONT>&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>(X)</FONT>&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="98%" colSpan=4><FONT face=serif size=2>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
      SECURITIES</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3><FONT face=serif size=2>EXCHANGE ACT OF 1934</FONT>&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3>&nbsp;</TD>
    <TD noWrap align=left width="58%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>For the quarterly
      period ended</FONT>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><FONT size=2>March 31, 2009</FONT></TD>
    <TD noWrap align=left width="38%">&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="98%" colSpan=4><FONT face=serif size=2>OR</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>(&nbsp;&nbsp;
      )</FONT>&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%" colSpan=4><FONT face=serif size=2>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
      SECURITIES</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3><FONT face=serif size=2>EXCHANGE ACT OF 1934</FONT>&nbsp;</TD>
    <TD noWrap align=left width="58%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="40%" colSpan=3>&nbsp;</TD>
    <TD noWrap align=left width="58%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%" colSpan=4><FONT face=serif size=2>For
      the transition period from ______________</FONT><FONT face=serif size=2>to
      ______________</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>Commission File Number
<U>0-19034</U></FONT></P>
<P align=center><U><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.</FONT></U> <FONT face=serif size=2><BR>(Exact name of registrant as
specified in its charter)</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><U><FONT face=serif size=2>New
      York</FONT></U>&nbsp;</TD>
    <TD noWrap align=center width="49%"><U><FONT face=serif size=2>13-3444607</FONT></U>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>(State or
      other jurisdiction of</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>(I.R.S.
      Employer Identification No.)</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>incorporation
      or organization)</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%">&nbsp;</TD></TR></TABLE><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>777 Old Saw
      Mill River Road</FONT>&nbsp;</TD>
    <TD noWrap align=left width="49%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><U><FONT face=serif size=2>Tarrytown,
      New York</FONT></U>&nbsp;</TD>
    <TD noWrap align=center width="49%"><U><FONT face=serif size=2>10591-6707</FONT></U>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>(Address of
      principal executive offices)</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>(Zip
      Code)</FONT>&nbsp;</TD></TR></TABLE><BR>
<P align=center><U><FONT face=serif size=2>(914) 347-7000</FONT></U> <FONT face=serif size=2><BR></FONT><FONT face=serif size=2>(Registrant&#146;s telephone
number, including area code)</FONT></P>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant (1) has filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90
days.</FONT></P>
<P align=center><FONT face=serif size=2>Yes</FONT> <U><FONT face=serif size=2>X</FONT></U><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No __</FONT></P>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant has submitted electronically and posted on its corporate Web site, if
any, every Interactive Data File required to be submitted and posted pursuant to
Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required to submit
and post such files).</FONT></P>
<P align=center><FONT face=serif size=2>Yes
__&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No __</FONT></P>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See definitions of &#147;large accelerated
filer&#148;, &#147;accelerated filer&#148;, and &#147;smaller reporting company&#148; in Rule 12b-2 of
the Exchange Act.</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>Large accelerated
      filer</FONT>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><FONT face=serif size=2><FONT size=3>&nbsp;</FONT>
    X</FONT>&nbsp;</TD>
    <TD noWrap align=left width="50%">&nbsp;</TD>
    <TD noWrap align=left width="46%"><FONT face=serif size=2>Accelerated
      filer</FONT>&nbsp; __</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>Non-accelerated
      filer</FONT>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="50%"><FONT face=serif size=2>&nbsp;(Do not
      check if a smaller reporting company)</FONT>&nbsp;</TD>
    <TD noWrap align=left width="46%"><FONT face=serif size=2>Smaller
      reporting company</FONT>&nbsp; __</TD></TR></TABLE><BR>
<P align=justify><FONT face=serif size=2>Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).</FONT></P>
<P align=center><FONT face=serif size=2>Yes
__&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No</FONT> <U><FONT face=serif size=2>X</FONT></U><FONT face=serif size=2></FONT></P>
<P align=justify><FONT face=serif size=2>Number of shares outstanding of each of
the registrant&#146;s classes of common stock as of April 14, 2009:</FONT></P>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="60%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><U><FONT face=serif size=2>Class of
      Common Stock</FONT></U>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2><U>Number of
      Shares</U></FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>Class A Stock,
      $0.001 par value</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>&nbsp;2,246,698</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="50%"><FONT face=serif size=2>Common Stock,
      $0.001 par value</FONT>&nbsp;</TD>
    <TD noWrap align=center width="49%"><FONT face=serif size=2>77,845,431</FONT>&nbsp;</TD></TR></TABLE></DIV><BR>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=center><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS, INC.
<BR>Table of Contents <BR>March 31, 2009</FONT></B></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=center width="11%" colSpan=2><FONT face=serif size=2><FONT size=3>&nbsp;</FONT><STRONG><U>Page
      Numbers</U></STRONG></FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><B><FONT face=serif size=2>PART I</FONT></B>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><B><FONT face=serif size=2>FINANCIAL INFORMATION</FONT></B>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 1</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Financial Statements</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed balance sheets (unaudited) at March 31, 2009 and December
      31, 2008<FONT size=3>&nbsp;</FONT></FONT></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT size=2>3</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed statements of operations (unaudited) for the three months
      ended March 31, 2009 and 2008<FONT size=3>&nbsp;</FONT></FONT></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT size=2>4</FONT>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed statement of stockholders&#146; equity (unaudited) for the
      three months ended March 31, 2009<FONT size=3>&nbsp;</FONT></FONT></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT size=2>5</FONT>&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Condensed statements of cash flows (unaudited) for the three months
      ended March 31, 2009 and 2008<FONT size=3>&nbsp;</FONT></FONT></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT size=2>6</FONT>&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Notes to condensed financial statements (unaudited)</FONT>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>7-10</FONT>&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 2</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2><U>Management's Discussion and Analysis of Financial Condition and
      Results of Operations</U><FONT size=3>&nbsp;</FONT></FONT></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT size=2>11-28</FONT>&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 3</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Quantitative and Qualitative Disclosures About Market
      Risk</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>29</FONT>&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 4</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Controls and Procedures</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>29</FONT>&nbsp;</TD></TR>
  <TR>
    <TD width="100%" colSpan=5>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><B><FONT face=serif size=2>PART II</FONT></B>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><B><FONT face=serif size=2>OTHER INFORMATION</FONT></B>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 1</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Legal Proceedings</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>29</FONT>&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 1A</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Risk Factors</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>29-44</FONT>&nbsp;</TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="6%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><U><FONT face=serif size=2>Item 6</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><U><FONT face=serif size=2>Exhibits</FONT></U>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>44</FONT>&nbsp;</TD></TR>
  <TR>
    <TD width="100%" colSpan=5>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=3><B><FONT face=serif size=2>SIGNATURE PAGE</FONT></B>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0><FONT face=serif size=2>45</FONT>&nbsp;</TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=left><B><FONT face=serif>PART I. FINANCIAL INFORMATION<BR>ITEM 1.
FINANCIAL STATEMENTS</FONT></B></P>
<P align=left><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR></FONT></B><B><FONT face=serif size=2>CONDENSED BALANCE SHEETS AT MARCH
31, 2009 AND DECEMBER 31, 2008 (Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(In thousands, except share data)</FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>March 31,</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="7%" colSpan=3><B><FONT face=serif size=2>December 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=center width="85%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR>
    <TD noWrap align=center width="100%" bgColor=#c0c0c0 colSpan=9><STRONG><FONT size=2>ASSETS</FONT></STRONG></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT face=serif size=2>Current
      assets</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash
      equivalents</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>199,097</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>247,796</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Marketable
      securities</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>216,785</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>226,954</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Accounts
      receivable from the sanofi-aventis Group</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>44,576</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>33,302</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Accounts
      receivable - other</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>3,633</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>1,910</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Prepaid
      expenses and other current assets</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>19,700</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>11,480</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total current assets</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>483,791</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>521,442</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="85%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT face=serif size=2>Restricted cash</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>1,650</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>1,650</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT face=serif size=2>Marketable
      securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>78,460</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>51,061</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT face=serif size=2>Property, plant, and equipment, at cost, net of
    accumulated</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>depreciation
      and amortization</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>109,840</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>87,853</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT face=serif size=2>Other
      assets</FONT>&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>7,680</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face=serif size=2>8,032</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total assets</FONT></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>681,421</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>670,038</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="85%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD align=center width="100%" bgColor=#c0c0c0 colSpan=9><B><FONT face=serif size=2>LIABILITIES and STOCKHOLDERS' EQUITY</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT face=serif size=2>Current
      liabilities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Accounts
      payable and accrued expenses</FONT></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>44,832</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>36,168</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Deferred
      revenue from sanofi-aventis, current portion</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>21,525</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>21,390</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Deferred
      revenue - other, current portion</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>36,756</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>26,114</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total current liabilities</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>103,113</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>83,672</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="85%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT face=serif size=2>Deferred revenue from sanofi-aventis</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>100,474</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>105,586</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT face=serif size=2>Deferred revenue
      - other</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>54,364</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>56,835</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT face=serif size=2>Other long term liabilities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>13,150</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>5,093</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total liabilities</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>271,101</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face=serif size=2>251,186</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="85%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT face=serif size=2>Commitments and contingencies</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="85%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT face=serif size=2>Stockholders' equity</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Preferred
      stock, $.01 par value; 30,000,000 shares authorized; issued
      and</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>outstanding-none</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Class A
      Stock, convertible, $.001 par value; 40,000,000 shares
      authorized;</FONT></FONT>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>shares issued and outstanding - 2,246,698 in 2009 and
      2,248,698 in 2008</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Common Stock,
      $.001 par value; 160,000,000 shares authorized;</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>shares issued and outstanding - 77,841,540 in 2009 and
      77,642,203 in 2008</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>78</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>78</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Additional
      paid-in capital</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>1,304,896</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>1,294,813</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Accumulated
      deficit</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(893,408</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=2>(875,927</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="85%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Accumulated other comprehensive loss</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(1,248</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>(114</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total stockholders' equity</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>410,320</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="5%"><FONT face=serif size=2>418,852</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="85%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total liabilities and stockholders'
    equity</FONT></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>681,421</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=2>670,038</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR></TABLE>
<P>&nbsp;</P>
<P><BR>&nbsp;</P>
<P align=center>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD width="100%">
      <P align=center><B><FONT face=serif size=2>The accompanying notes are an
      integral part of the financial statements.</FONT></B></P></TD></TR>
  <TR>
    <TD width="100%">&nbsp;</TD></TR>
  <TR>
    <TD style="BORDER-TOP: #000000 2pt double" width="100%">&nbsp;</TD></TR>
  <TR>
    <TD width="100%">
      <P align=center><FONT face=serif size=2>3</FONT></P></TD></TR></TABLE>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=left><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR></FONT></B><B><FONT face=serif size=2>CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(In thousands, except
per share data)</FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="13%" colSpan=7><B><FONT face=serif size=2>Three months ended March 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Revenues</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contract research and
      development from sanofi-aventis</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>49,660</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>35,734</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Other
      contract research and development</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>11,430</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>10,649</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Technology
      licensing</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>10,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>10,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Net product
      sales</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>3,891</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>74,981</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>56,383</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Research and
      development</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>82,146</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>61,270</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Selling,
      general, and administrative</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>11,674</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>11,024</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Cost of goods
      sold</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>392</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>94,212</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>72,294</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Loss from operations</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(19,231</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(15,911</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Other income (expense)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Investment
      income</FONT></FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>1,750</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>7,304</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Interest expense</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(3,011</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>1,750</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>4,293</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(17,481</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(11,618</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 2pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Net loss per share, basic and diluted</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(0.22</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(0.15</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Weighted average shares outstanding, basic and diluted</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>79,498</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>78,493</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR></TABLE>
<P>&nbsp;</P>
<P><BR>&nbsp;</P>
<P align=center>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD width="100%">
      <P align=center><B><FONT face=serif size=2>The accompanying notes are an
      integral part of the financial statements.</FONT></B></P></TD></TR>
  <TR>
    <TD width="100%">&nbsp;</TD></TR>
  <TR>
    <TD style="BORDER-TOP: #000000 2pt double" width="100%">&nbsp;</TD></TR>
  <TR>
    <TD width="100%">
      <P align=center><FONT face=serif size=2>4</FONT></P></TD></TR></TABLE>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=left><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR></FONT></B><B><FONT face=serif size=2>CONDENSED STATEMENT OF
STOCKHOLDERS' EQUITY (Unaudited)<BR></FONT></B><B><FONT face=serif size=1></FONT></B><B><FONT face=serif size=2>For the three months ended March
31, 2009<BR></FONT></B><B><I><FONT face=serif size=2>(In
thousands)</FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="38%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="5%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=1>Accumulated</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%"></TD>
    <TD noWrap align=center width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%"></TD>
    <TD noWrap align=center width="4%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=1>Additional</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=1>Other</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=1>Total</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="6%"></TD>
    <TD noWrap align=center width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=5><B><FONT face=serif size=1>Class A Stock</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=4><B><FONT face=serif size=1>Common Stock</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=1>Paid-in</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=3><B><FONT face=serif size=1>Accumulated</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=1>Comprehensive</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=1>Stockholders'</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=1>Comprehensive</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=1>Shares</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=1>Amount</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%"><B><FONT face=serif size=1>Shares</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face=serif size=1>Amount</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><B><FONT face=serif size=1>Capital</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=3><B><FONT face=serif size=1>Deficit</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=1>Loss</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=1>Equity</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face=serif size=1>Loss</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%" bgColor=#c0c0c0><B><FONT face=serif size=1>Balance, December 31, 2008</FONT></B></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>&nbsp;&nbsp; 2,249</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>2</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=1>77,642</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=1>78</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>1,294,813</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=1>(875,927</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=1>(114</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>)</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>$</FONT></TD>
    <TD align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=1>418,852</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%"><FONT face=serif size=1>Issuance of
      Common Stock in connection with</FONT></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="6%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="6%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="6%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%"><FONT face=serif size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exercise of stock options, net
      of shares tendered</FONT></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=1>117</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=1>1,038</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="6%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=1>1,038</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="6%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%" bgColor=#c0c0c0><FONT face=serif size=1>Issuance of Common Stock in connection with</FONT></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%" bgColor=#c0c0c0><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Company
      401(k) Savings Plan contribution</FONT></FONT></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face=serif size=1>81</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>1,391</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=1>1,391</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%"><FONT face=serif size=1>Conversion of
      Class A Stock to Common Stock</FONT></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=1>(2</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=1>2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="6%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="6%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="6%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%" bgColor=#c0c0c0><FONT face=serif size=1>Stock-based compensation expense</FONT></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=1>7,654</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=1>7,654</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%"><FONT face=serif size=1>Net
    loss</FONT></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="5%"><FONT face=serif size=1>(17,481</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="6%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=1>(17,481</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD noWrap align=right width="6%"><FONT face=serif size=1>(17,481</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=1>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="38%" bgColor=#c0c0c0><FONT face=serif size=1>Change in net unrealized loss on</FONT></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="6%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="38%" bgColor=#c0c0c0><FONT size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>marketable securities</FONT></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=1>(1,134</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=1>(1,134</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="6%" bgColor=#c0c0c0><FONT face=serif size=1>(1,134</FONT></TD>
    <TD style="BORDER-BOTTOM: #c0c0c0 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=1>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="38%"><B><FONT face=serif size=1>Balance, March 31,
    2009</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%"><FONT face=serif size=1>2,247</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=1>2</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="5%"><FONT face=serif size=1>77,842</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%"><FONT face=serif size=1>78</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="4%"><FONT face=serif size=1>1,304,896</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="5%"><FONT face=serif size=1>(893,408</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="6%"><FONT face=serif size=1>(1,248</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="1%"><FONT face=serif size=1>)</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="6%"><FONT face=serif size=1>410,320</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=1>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="6%"><FONT face=serif size=1>(18,615</FONT></TD>
    <TD style="BORDER-BOTTOM: #ffffff 2pt solid" noWrap align=left width="1%"><FONT face=serif size=1>)</FONT></TD></TR></TABLE>
<P>&nbsp;</P>
<P><BR>&nbsp;</P>
<P align=center>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD width="100%">
      <P align=center><B><FONT face=serif size=2>The accompanying notes are an
      integral part of the financial statements.</FONT></B></P></TD></TR>
  <TR>
    <TD width="100%">&nbsp;</TD></TR>
  <TR>
    <TD style="BORDER-TOP: #000000 2pt double" width="100%">&nbsp;</TD></TR>
  <TR>
    <TD width="100%">
      <P align=center><FONT face=serif size=2>5</FONT></P></TD></TR></TABLE>
<HR align=center width="100%" noShade SIZE=1>
<PAGE>
<P align=left><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR></FONT></B><B><FONT face=serif size=2>CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)<BR></FONT></B><B><I><FONT face=serif size=2>(In
thousands)</FONT></I></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="13%" colSpan=7><B><FONT face=serif size=2>Three months ended March 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Cash flows from operating activities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net loss</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(17,481</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(11,618</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Adjustments
      to reconcile net loss to net cash used in</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>operating activities</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Depreciation and amortization</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>2,724</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>2,946</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Non-cash compensation expense</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>7,654</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>8,286</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Changes in assets and liabilities</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Increase in accounts receivable</FONT></FONT>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(12,997</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(14,640</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>(Increase) decrease in prepaid expenses and other
      assets</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(8,611</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>1,493</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Increase in deferred revenue</FONT></FONT>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>3,194</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>3,200</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Increase (decrease) in accounts payable, accrued
      expenses,</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      and other liabilities</FONT>&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>15,318</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(7,564</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Total adjustments</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>7,282</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(6,279</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Net cash used in operating activities</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(10,199</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(17,897</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Cash flows from investing activities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Purchases of
      marketable securities</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(100,315</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face=serif size=2>(91,518</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Sales or
      maturities of marketable securities</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>82,694</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>132,509</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Capital
      expenditures</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(21,917</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>(3,047</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Net cash (used in) provided by investing activities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(39,538</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>37,944</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Cash flows from financing activities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="4%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%"><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif>Net proceeds
      from the issuance of Common Stock</FONT></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>1,038</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%"><FONT face=serif size=2>1,903</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=serif>Net cash provided by financing
activities</FONT></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>1,038</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>1,903</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Net (decrease) increase in cash and cash equivalents</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>(48,699</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>21,950</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Cash and cash equivalents at beginning of period</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>247,796</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>498,925</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="86%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="4%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="4%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="86%" bgColor=#c0c0c0><FONT face=serif size=2>Cash and cash equivalents at end of period</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>199,097</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="4%" bgColor=#c0c0c0><FONT face=serif size=2>520,875</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE><BR>
<P>&nbsp;</P>
<P><BR>&nbsp;</P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD align=center width="100%">
      <P align=center><B><FONT face=serif size=2>The accompanying notes are an
      integral part of the financial statements.</FONT></B></P></TD></TR>
  <TR>
    <TD width="100%">&nbsp;</TD></TR>
  <TR>
    <TD style="BORDER-TOP: #000000 2pt double" width="100%">&nbsp;</TD></TR>
  <TR>
    <TD width="100%">
      <P align=center><FONT face=serif size=2>6</FONT></P></TD></TR></TABLE>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements
(Unaudited)</FONT></B><BR><B><I><FONT face=serif size=2>(Unless otherwise noted,
dollars in thousands, except per share data)</FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>1.</FONT></B><B><FONT face=serif size=2></FONT></B> <B><FONT face=serif size=2>Interim Financial
Statements</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
interim Condensed Financial Statements of Regeneron Pharmaceuticals, Inc.
(&#147;Regeneron&#148; or the &#147;Company&#148;) have been prepared in accordance with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do
not include all information and disclosures necessary for a presentation of the
Company&#146;s financial position, results of operations, and cash flows in
conformity with accounting principles generally accepted in the United States of
America. In the opinion of management, these financial statements reflect all
adjustments, consisting only of normal recurring accruals, necessary for a fair
presentation of the Company&#146;s financial position, results of operations, and
cash flows for such periods. The results of operations for any interim periods
are not necessarily indicative of the results for the full year. The December
31, 2008 Condensed Balance Sheet data were derived from audited financial
statements, but do not include all disclosures required by accounting principles
generally accepted in the United States of America. These financial statements
should be read in conjunction with the financial statements and notes thereto
contained in the Company&#146;s Annual Report on Form 10-K for the year ended
December 31, 2008.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in research and development expenses is the Company&#146;s share of VEGF Trap-Eye
development expenses incurred by Bayer HealthCare LLC, including the Company&#146;s
share of Bayer HealthCare&#146;s estimated VEGF Trap-Eye development expenses for the
most recent interim fiscal quarter. The Bayer HealthCare estimate is adjusted to
agree with actual expenses for such quarter in the subsequent interim fiscal
quarter.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Effective
in the first quarter of 2009, the estimated useful lives of laboratory and other
equipment, which is a component of property, plant, and equipment, has been
extended from 3 &#150; 5 years to 3 &#150; 10 years. The effect of this change in estimate
was to lower depreciation expense by $0.2 million for the first quarter of 2009.
There was no impact on the net loss per share as a result of this change in
estimate.</FONT></P>
<P align=justify><B><FONT face=serif size=2>2.</FONT></B><B><FONT face=serif size=2></FONT></B> <B><FONT face=serif size=2>ARCALYST<SUP>&#174;</SUP></FONT></B>
<B><FONT face=serif size=2>(rilonacept) Product Revenue</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
February 2008, the Company received marketing approval from the FDA for ARCALYST
for the treatment of CAPS. For the three months ended March 31, 2009, the
Company recognized as revenue $3.9 million of ARCALYST net product sales for
which the right of return no longer existed and rebates could be reasonably
estimated. At March 31, 2009 and 2008, deferred revenue related to ARCALYST net
product sales totaled $4.2 million and $0.8 million, respectively.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Cost of
goods sold related to ARCALYST sales totaled $0.4 million for the three months
ended March 31, 2009 and consisted primarily of royalties. To date, ARCALYST
shipments to the Company&#146;s customers consisted of supplies of inventory
manufactured and expensed prior to FDA approval of ARCALYST; therefore, the
costs of these supplies were not included in costs of goods sold. At March 31,
2009, the Company had $0.3 million of inventoried work-in-process costs related
to ARCALYST, which is included in prepaid expenses and other current assets.
There were no capitalized inventory costs at December 31, 2008.</FONT></P>
<P align=center><FONT face=serif size=2>7</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><FONT face=serif size=2><B>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements (Unaudited)<BR><EM>(Unless
otherwise noted, dollars in thousands, except per share
data)</EM></B></FONT></P>
<P align=justify><FONT face=serif size=2><STRONG>3. Per Share
Data</STRONG></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company&#146;s basic and diluted net loss per share amounts have been computed by
dividing net loss by the weighted average number of shares of Common Stock and
Class A Stock outstanding. Net loss per share is presented on a combined basis,
inclusive of Common Stock and Class A Stock outstanding, as each class of stock
has equivalent economic rights. For the three months ended March 31, 2009 and
2008, the Company reported net losses; therefore, no common stock equivalents
were included in the computation of diluted net loss per share for these
periods, since such inclusion would have been antidilutive. The calculations of
basic and diluted net loss per share are as follows:</FONT></P>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="87%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%" colSpan=7><FONT face=serif size=2>Three Months Ended March
31,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Net
      loss (Numerator)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(17,481</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(11,618</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Weighted-average shares, in thousands (Denominator)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>79,498</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>78,493</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="99%" colSpan=9>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Basic
      and diluted net loss per share</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(0.22</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(0.15</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Shares
issuable upon the exercise of stock options, vesting of restricted stock awards,
and conversion of convertible debt, which have been excluded from the March 31,
2009 and 2008 diluted per share amounts because their effect would have been
antidilutive, include the following:</FONT></P>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="89%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><FONT face=serif size=2>Three months ended March
31,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Stock
      Options:</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average number, in
      thousands</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>20,216</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>17,680</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average exercise
      price</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>17.55</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>17.16</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Restricted Stock:</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average number, in
      thousands</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="3%"><FONT face=serif size=2>500</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>500</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=7>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Convertible Debt:</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weighted average number, in
      thousands</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="3%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>6,611</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conversion price</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="3%" bgColor=#c0c0c0></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>30.25</FONT></TD></TR></TABLE><BR>
<P align=justify><B><FONT face=serif size=2>4.</FONT></B><B><FONT face=serif size=2></FONT></B> <B><FONT face=serif size=2>Statement of Cash
Flows</FONT></B></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Supplemental disclosure of noncash
investing and financing activities:</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in accounts payable and accrued expenses at March 31, 2009 and December 31, 2008
were $9.8 million and $7.0 million, respectively, of accrued capital
expenditures. Included in accounts payable and accrued expenses at March 31,
2008 and December 31, 2007 were $1.5 million and $1.7 million, respectively, of
accrued capital expenditures.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in accounts payable and accrued expenses at December 31, 2008 and 2007 were $1.5
million and $1.1 million, respectively, of accrued Company 401(k) Savings Plan
contribution expense. In the first quarter of 2009 and 2008, the Company
contributed 81,086 and 58,575 shares, respectively, of Common Stock to the
401(k) Savings Plan in satisfaction of these obligations.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Included
in marketable securities at March 31, 2009 and December 31, 2008 were $2.5
million and $1.7 million, respectively, of accrued interest income. Included in
marketable securities at March 31, 2008 and December 31, 2007 were $2.1 million
and $2.2 million, respectively, of accrued interest income.</FONT></P>
<P align=center><FONT face=serif size=2>8</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><FONT face=serif size=2><B>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements (Unaudited)<BR><EM>(Unless
otherwise noted, dollars in thousands, except per share
data)</EM></B></FONT></P>
<P align=justify><FONT face=serif size=2><STRONG>5. Fair Value of Financial
Assets</STRONG></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company&#146;s assets that are measured at fair value on a recurring basis, and
subject to the disclosure requirements of Statement of Financial Accounting
Standards No. (&#147;SFAS&#148;) 157, <I>Fair Value Measurements</I>, at March 31, 2009
and December 31, 2008, were as follows:</FONT></P>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="80%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="14%" colSpan=8><FONT face=serif size=2>Fair Value Measurements at Reporting
      Date Using</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Quoted Prices in</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Significant Other</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Significant</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Fair
      Value at</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Active Markets for</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Observable</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Unobservable</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>March
      31,</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Identical Assets</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="80%"><FONT face=serif size=2>Description</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>(Level 1)</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>(Level 2)</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp; &nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>(Level 3)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" bgColor=#c0c0c0><FONT face=serif size=2>Available-for-sale marketable securities</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>295,245</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>3,138</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>292,007</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>100</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=13>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="14%" colSpan=8><FONT face=serif size=2>Fair Value Measurements at Reporting
      Date Using</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Quoted Prices in</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Significant Other</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Significant</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Fair
      Value at</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;</TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Active Markets for</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Observable</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Unobservable</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>December 31,</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Identical Assets</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>Inputs</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="80%"><FONT face=serif size=2>Description</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2008</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>(Level 1)</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>(Level 2)</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>(Level 3)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="80%" bgColor=#c0c0c0><FONT face=serif size=2>Available-for-sale marketable securities</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>278,015</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>3,608</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>247,307</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>100</FONT></TD></TR></TABLE><BR>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There
were no realized or unrealized gains or losses related to the Company&#146;s Level 3
marketable securities for the three months ended March 31, 2009 and 2008. In
addition, there were no purchases, sales, or maturities of Level 3 marketable
securities, and no transfers of marketable securities between the Level 2 and
Level 3 classifications, during the quarters ended March 31, 2009 and
2008.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>On a
quarterly basis, the Company reviews its portfolio of marketable securities,
using both quantitative and qualitative factors, to determine if declines in
fair value below cost are other-than-temporary. During the three months ended
March 31, 2009 and 2008, the Company did not record any charges for
other-than-temporary impairment of its marketable securities. However, the
current economic environment, the deterioration in the credit quality of some of
the issuers of securities that the Company holds, and the recent volatility of
securities markets increase the risk that there could be further declines in the
market value of marketable securities in the Company&#146;s investment portfolio and
that such declines could result in charges against income in future periods for
other-than-temporary impairments, and such amounts could be material.</FONT></P>
<P align=justify><B><FONT face=serif size=2>6.</FONT></B><B><FONT face=serif size=2></FONT></B> <B><FONT face=serif size=2>Accounts Payable and Accrued
Expenses</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Accounts
payable and accrued expenses as of March 31, 2009 and December 31, 2008 consist
of the following:</FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="89%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>March
      31,</FONT></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>December 31,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Accounts payable</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>17,779</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>6,268</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"><FONT face=serif size=2>Payable to Bayer
      HealthCare</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>&nbsp;</FONT></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>9,799</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Accrued
      payroll and related costs</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>8,352</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>5,948</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"><FONT face=serif size=2>Accrued clinical trial
      expense</FONT></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>6,558</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="1%"></TD>
    <TD align=right width="3%"><FONT face=serif size=2>4,273</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0><FONT face=serif size=2>Accrued
      property, plant, and equipment expenses</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>8,069</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>5,994</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%"><FONT face=serif size=2>Accrued expenses,
      other</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT face=serif size=2>4,074</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT face=serif size=2>3,886</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="89%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>44,832</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>36,168</FONT></TD></TR></TABLE></DIV><BR>
<P align=center><FONT face=serif size=2>9</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><FONT face=serif size=2><B>REGENERON PHARMACEUTICALS,
INC.<BR>Notes to Condensed Financial Statements (Unaudited)<BR><EM>(Unless
otherwise noted, dollars in thousands, except per share
data)</EM></B></FONT></P>
<P align=justify><FONT face=serif size=2><B>7. Comprehensive Loss</B></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Company presents comprehensive income (loss) in accordance with SFAS 130,
<I>Reporting Comprehensive Income</I>. Comprehensive loss of the Company
includes net loss adjusted for the change in net unrealized gain (loss) on
marketable securities. For the three months ended March 31, 2009 and 2008, the
components of comprehensive loss are:</FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 12pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="87%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%" colSpan=7><FONT face=serif size=2>Three months ended March
31,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%"></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>2009</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><FONT face=serif size=2>2008</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>Net
      loss</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(17,481</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(11,618</FONT></TD>
    <TD align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%"><FONT face=serif size=2>Change in net
      unrealized gain (loss) on marketable securities</FONT></TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT face=serif size=2>(1,134</FONT></TD>
    <TD align=left width="1%"><FONT face=serif size=2>)</FONT></TD>
    <TD align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=right width="3%"><FONT face=serif size=2>658</FONT></TD>
    <TD align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="87%" bgColor=#c0c0c0><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total comprehensive
    loss</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(18,615</FONT></TD>
    <TD style="PADDING-BOTTOM: 2px" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD>
    <TD align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" align=right width="3%" bgColor=#c0c0c0><FONT face=serif size=2>(10,960</FONT></TD>
    <TD style="PADDING-BOTTOM: 2px" align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><B><FONT face=serif size=2>8.</FONT></B><B><FONT face=serif size=2></FONT></B> <B><FONT face=serif size=2>Legal Matters</FONT></B> <FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>From time
to time, the Company is a party to legal proceedings in the course of its
business. The Company does not expect any such current legal proceedings to have
a material adverse effect on the Company&#146;s business or financial
condition.</FONT></P>
<P align=justify><B><FONT face=serif size=2>9.</FONT></B><B><FONT face=serif size=2></FONT></B> <B><FONT face=serif size=2>Future Impact of Recently Issued
Accounting Standards</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In April
2009, the Financial Accounting Standards Board (&#147;FASB&#148;) issued FASB Staff
Position (&#147;FSP&#148;) FAS 107-1 and APB 28-1,</FONT> <I><FONT face=serif size=2>Interim Disclosures about Fair Value of Financial Instruments.</FONT></I>
<FONT face=serif size=2>This FSP amends SFAS 107,</FONT> <I><FONT face=serif size=2>Disclosures about Fair Value of Financial Instruments,</FONT></I> <FONT face=serif size=2>to require entities to provide disclosures about the fair
value of financial instruments in interim financial information. This FSP also
amends APB Opinion No. 28,</FONT> <I><FONT face=serif size=2>Interim Financial
Reporting,</FONT></I> <FONT face=serif size=2>to require those disclosures in
summarized financial information at interim reporting periods. In addition, an
entity shall disclose in the body or in the accompanying notes of its summarized
financial information for interim reporting periods and in its financial
statements for annual reporting periods the fair value of all financial
instruments for which it is practicable to estimate that value, whether
recognized or not recognized in the statement of financial position, as required
by SFAS 107. The Company is required to adopt FSP FAS 107-1 and APB 28-1 for the
quarter ended June 30, 2009. Management does not anticipate that the adoption of
FSP FAS 107-1 and APB 28-1 will have a material impact on the Company&#146;s
financial statements.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In April
2009, the FASB issued FSP FAS 115-2 and FAS 124-2,</FONT> <I><FONT face=serif size=2>Recognition and Presentation of Other-Than-Temporary
Impairments.</FONT></I> <FONT face=serif size=2>This FSP changes existing
guidance for determining whether an impairment to debt securities is other than
temporary; replaces the existing requirement that management assert it has both
the intent and ability to hold an impaired security until recovery with a
requirement that management assert, (</FONT><I><FONT face=serif size=2>a</FONT></I><FONT face=serif size=2>) it does not have the intent to sell
the security; and (</FONT><I><FONT face=serif size=2>b</FONT></I><FONT face=serif size=2>) it is more likely than not it will not have to sell the
security before recovery of its cost basis; requires that an entity recognize
noncredit losses on held-to-maturity debt securities in other comprehensive
income and amortize that amount over the remaining life of the security in a
prospective manner by offsetting the recorded value of the asset unless the
security is subsequently sold or there are additional credit losses; and
requires entities to present the total other-than-temporary impairment in the
statement of earnings with an offset for the amount recognized in other
comprehensive income. When adopting FSP FAS 115-2 and FAS 124-2, entities are
required to record a cumulative-effect adjustment as of the beginning of the
period of adoption to reclassify the noncredit component of a previously
recognized other-temporary impairment from retained earnings to accumulated
other comprehensive income if the entity does not intend to sell the security
and it is not more likely than not that the entity will be required to sell the
security before recovery. The Company is required to adopt FSP FAS 115-2 and FAS
124-2 for the quarter ended June 30, 2009. Management does not anticipate that
the adoption of FSP FAS 115-2 and FAS 124-2 will have a material impact on the
Company&#146;s financial statements.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In April
2009, the FASB issued FSP FAS 157-4,</FONT> <I><FONT face=serif size=2>Determining Fair Value When the Volume and Level of Activity for the
Asset or Liability Have Significantly Decreased and Identifying Transactions
That Are Not Orderly.</FONT></I> <FONT face=serif size=2>This FSP affirms that
the objective of fair value when the market for an asset is not active is the
price that would be received to sell the asset in an orderly transaction;
clarifies and includes additional factors for determining whether there has been
a significant decrease in market activity for an asset when the market for that
asset is not active; and eliminates the proposed presumption that all
transactions are distressed (not orderly) unless proven otherwise. The FSP
instead requires an entity to base its conclusion about whether a transaction
was not orderly on the weight of the evidence. The Company is required to adopt
FSP FAS 157-4 for the quarter ended June 30, 2009. Management does not
anticipate that the adoption of FSP FAS 157-4 will have a material impact on the
Company&#146;s financial statements.</FONT></P>
<P align=justify><FONT face=serif size=2><STRONG>10. Subsequent Event -
Amendment to Operating Lease</STRONG></FONT></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company leases laboratory and
office facilities in Tarrytown, New York. In December 2006, the Company entered
into a new agreement (which was amended in October 2007 and September 2008) to
lease laboratory and office space at the Company&#146;s current Tarrytown location,
including space that is now under construction and expected to be completed in
mid-2009 (the &#147;new facilities&#148;). The term of the lease commenced effective June
2008 and will expire in June 2024. In April 2009, the Company amended the
operating lease agreement to increase the amount of space the Company will
lease. As amended, the lease contains early termination options for the portion
of the space that excludes the new facilities. Other terms and conditions, as
previously described in the Company&#146;s Annual Report on Form 10-K for the year
ended December 31, 2008, remain unchanged. In connection with the lease
amendment, in April 2009, the Company terminated an April 2008 sublease for
space in Tarrytown, New York.</FONT></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In connection with the April 2009
amendment to the operating lease, the Company&#146;s total estimated future minimum
noncancelable lease commitments under operating leases, previously disclosed in
the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2008,
will increase to $9.4 million, $14.5 million, $14.7 million, $13.7 million, and
$15.1 million for the years ended December 31, 2009, 2010, 2011, 2012, and 2013,
respectively, and increase to $182.5 million, in the aggregate, for years
subsequent to 2013.</FONT></P>
<P align=center><FONT face=serif size=2>10</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>ITEM 2. MANAGEMENT&#146;S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT face=serif size=2>The
discussion below contains forward-looking statements that involve risks and
uncertainties relating to future events and the future financial performance of
Regeneron Pharmaceuticals, Inc., and actual events or results may differ
materially. These statements concern, among other things, the possible success
and therapeutic applications of our product candidates and research programs,
anticipated sales of our marketed product, the timing and nature of the clinical
and research programs now underway or planned, and the future sources and uses
of capital and our financial needs. These statements are made by us based on
management's current beliefs and judgment. In evaluating such statements,
stockholders and potential investors should specifically consider the various
factors identified under the caption &#147;Risk Factors&#148; which could cause actual
results to differ materially from those indicated by such forward-looking
statements. We do not undertake any obligation to update publicly any
forward-looking statement, whether as a result of new information, future
events, or otherwise, except as required by law.</FONT></I></P>
<P align=justify><B><FONT face=serif size=2>Overview</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Regeneron
Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops,
and commercializes pharmaceutical products for the treatment of serious medical
conditions. We currently have one marketed product: ARCALYST<SUP>&#174;</SUP>
(rilonacept) Injection for Subcutaneous Use, which is available for prescription
in the United States for the treatment of Cryopyrin-Associated Periodic
Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and
Muckle-Wells Syndrome (MWS) in adults and children 12 and older. We also have
six clinical development programs, including three late-stage clinical programs.
Our late stage programs are aflibercept (VEGF Trap), which is being developed in
oncology in collaboration with the sanofi-aventis Group, VEGF Trap-Eye, which is
being developed in eye diseases using intraocular delivery in collaboration with
Bayer HealthCare LLC, and ARCALYST, which is being developed for the treatment
of gout. Our earlier stage clinical programs are REGN88, an antibody to the
interleukin-6 receptor (IL-6R), which is being developed in rheumatoid
arthritis, REGN421, an antibody to Delta-like ligand-4 (Dll4), which is being
developed in oncology, and REGN475, an antibody to Nerve Growth Factor (NGF),
which is being developed for the treatment of pain. All three of these
antibodies are being developed in collaboration with sanofi-aventis.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We expect
that our next generation of product candidates will be based on our proprietary
technologies for developing human monoclonal antibodies. Our antibody program is
being conducted primarily in collaboration with sanofi-aventis. Our preclinical
research programs are in the areas of oncology and angiogenesis, ophthalmology,
metabolic and related diseases, muscle diseases and disorders, inflammation and
immune diseases, bone and cartilage, pain, and cardiovascular
diseases.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our core
business strategy is to maintain a strong foundation in basic scientific
research and discovery-enabling technology and combine that foundation with our
clinical development and manufacturing capabilities to build a successful,
integrated biopharmaceutical company. However, developing and commercializing
new medicines entails significant risk and expense.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
believe that our ability to develop product candidates is enhanced by the
application of our <EM>VelociSuite</EM><SUP>TM</SUP> technology platforms. Our
discovery platforms are designed to identify specific genes of therapeutic
interest for a particular disease or cell type and validate targets through
high-throughput production of mammalian models. Our human monoclonal antibody
technology (<EM>VelocImmune<SUP>&#174;</SUP></EM>) and cell line expression
technologies (<EM>VelociMab<SUP>TM</SUP></EM>)&nbsp;may then be utilized to
design and produce new product candidates directed against the disease target.
Our first three antibody product candidates currently in clinical trials were
developed using <I>VelocImmune</I>. Over the course of the next several years,
we plan to advance an average of two to three new antibody product candidates
into clinical development each year. We continue to invest in the development of
enabling technologies to assist in our efforts to identify, develop, and
commercialize new product candidates.</FONT></P>
<P align=center><FONT face=serif size=2>11</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><U><FONT face=serif size=2>Commercial
Product:</FONT></U></B><B><FONT face=serif size=2></FONT></B></P>
<P align=justify><FONT face=serif size=2><STRONG><EM>ARCALYST<SUP>&#174;</SUP>
(rilonacept) &#150; Cryopyrin-Associated Periodic Syndromes
(CAPS)</EM></STRONG></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
February 2008, we received marketing approval from the U.S. Food and Drug
Administration (FDA) for ARCALYST<SUP>&#174;</SUP> (rilonacept) Injection for
Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes
(CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and
Muckle-Wells Syndrome (MWS) in adults and children 12 and older. We shipped
$10.7 million of ARCALYST to our distributors in 2008, and $4.3 million during
the first quarter of 2009. ARCALYST is a protein-based product designed to bind
the interleukin-1 (called IL-1) cytokine and prevent its interaction with cell
surface receptors. ARCALYST is the only therapy approved in the United States
for patients with CAPS, a group of rare, inherited, auto-inflammatory conditions
characterized by life-long, recurrent symptoms of rash, fever/chills, joint
pain, eye redness/pain, and fatigue. Intermittent, disruptive exacerbations or
flares can be triggered at any time by exposure to cooling temperatures, stress,
exercise, or other unknown stimuli. CAPS is caused by a range of mutations in
the gene NLRP3 (formerly known as <I>CIAS1</I>) which encodes a protein named
cryopyrin. In addition to FCAS and MWS, CAPS includes Neonatal Onset Multisystem
Inflammatory Disease (NOMID). ARCALYST has not been studied for the treatment of
NOMID.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In March
2008, ARCALYST became available for prescription in the United States and we
transitioned the patients who participated in the CAPS pivotal study from
clinical study drug to commercial supplies. In 2009, we expect to ship $15-20
million of ARCALYST to our U.S. distributors. In July 2008, we submitted a
Marketing Authorization Application (MAA) to the European Medicines Agency
(EMEA) for ARCALYST for the treatment of CAPS in the European Union.</FONT></P>
<P align=justify><B><U><FONT face=serif size=2>Clinical
Programs:</FONT></U></B><B><FONT face=serif size=2></FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>1. Aflibercept (VEGF Trap) &#150;
Oncology</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Aflibercept is a protein-based product candidate designed to bind all
forms of Vascular Endothelial Growth Factor-A (called VEGF-A, also known as
Vascular Permeability Factor or VPF) and the related Placental Growth Factor
(called PlGF), and prevent their interaction with cell surface receptors. VEGF-A
(and to a less validated degree, PlGF) is required for the growth of new blood
vessels (a process known as angiogenesis) that are needed for tumors to grow and
is a potent regulator of vascular permeability and leakage.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Aflibercept is being developed globally in cancer indications in
collaboration with sanofi-aventis. We and sanofi-aventis are enrolling patients
in four Phase 3 trials that are evaluating combinations of aflibercept with
standard chemotherapy regimens for the treatment of cancer. One trial is
evaluating aflibercept as a 2<SUP>nd</SUP> line treatment for metastatic
colorectal cancer (called VELOUR) in combination with FOLFIRI (folinic acid
(leucovorin), 5-fluorouracil, and irinotecan). A second trial is evaluating
aflibercept as a 1<SUP>st</SUP> line treatment for metastatic pancreatic cancer
in combination with gemcitabine (VANILLA). A third trial is evaluating
aflibercept as a 2<SUP>nd</SUP> line treatment for metastatic non-small cell
lung cancer in combination with docetaxel (VITAL). The fourth trial is
evaluating aflibercept as a 1<SUP>st</SUP> line treatment for metastatic
androgen-independent prostate cancer in combination with docetaxel/prednisone
(VENICE). All four trials are studying the current standard of chemotherapy care
for the cancer being studied with and without aflibercept. At the end of the
first quarter of 2009, each of the four Phase 3 trials was approximately
one-half enrolled, and initial data from the Phase 3 program are expected are
2010. In addition, a Phase 2 study of aflibercept in 1st-line metastatic
colorectal cancer in combination with folinic acid (leucovorin), 5-fluorouracil,
and oxaliplatin (AFFIRM) began recruiting patients in January 2009.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Aflibercept is also being studied in a Phase 2 single-agent study in
advanced ovarian cancer (AOC) patients with symptomatic malignant ascites (SMA).
This trial is now fully enrolled and initial data from this trial are expected
by mid-2009. The FDA has granted Fast Track designation to aflibercept for the
treatment of SMA.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition, multiple exploratory studies are being conducted in conjunction with
the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)
evaluating aflibercept as a single agent or in combination with chemotherapy
regimens in a variety of cancer indications.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>12</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>Aflibercept Collaboration with the
sanofi-aventis Group</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We and
sanofi-aventis U.S. (successor to Aventis Pharmaceuticals, Inc.) collaborate on
the development and commercialization of aflibercept globally. Under the terms
of our September 2003 collaboration agreement, as amended, we and sanofi-aventis
will share co-promotion rights and profits on sales, if any, of aflibercept
outside of Japan for disease indications included in our collaboration. In
Japan, we are entitled to a royalty of approximately 35% on annual sales of
aflibercept, subject to certain potential adjustments. We may also receive up to
$400 million in milestone payments upon receipt of specified marketing
approvals, including up to $360 million in milestone payments related to receipt
of marketing approvals for up to eight aflibercept oncology and other
indications in the United States or the European Union and up to $40 million
related to receipt of marketing approvals for up to five oncology indications in
Japan.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Under the
aflibercept collaboration agreement, as amended, agreed upon worldwide
development expenses incurred by both companies during the term of the agreement
will be funded by sanofi-aventis. If the collaboration becomes profitable, we
will be obligated to reimburse sanofi-aventis for 50% of aflibercept development
expenses in accordance with a formula based on the amount of development
expenses and our share of the collaboration profits and Japan royalties, or at a
faster rate at our option.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>2. VEGF Trap-Eye &#150; Ophthalmologic
Diseases</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>VEGF
Trap-Eye is a specially purified and formulated form of VEGF Trap for use in
intraocular applications. We and Bayer HealthCare are testing VEGF Trap-Eye in a
Phase 3 program in patients with the neovascular form of age-related macular
degeneration (wet AMD). We and Bayer HealthCare also initiated a Phase 2 study
of VEGF Trap-Eye in patients with diabetic macular edema (DME) in late 2008. Wet
AMD and diabetic retinopathy (which includes DME) are two of the leading causes
of adult blindness in the developed world. In both conditions, severe visual
loss is caused by a combination of retinal edema and neovascular proliferation.
We and Bayer HealthCare have also announced plans to initiate a Phase 3 program
later this year of VEGF Trap-Eye in the treatment of Central Retinal Vein
Occlusion (CRVO). Dosing of the first patient in this Phase 3 program will
entitle us to receive a $20.0 million milestone payment.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The Phase
3 trials in wet AMD, known as VIEW 1 and VIEW 2 (<U>V</U>EGF Trap:
<U>I</U>nvestigation of <U>E</U>fficacy and Safety in <U>W</U>et age-related
macular degeneration), are comparing VEGF Trap-Eye and ranibizumab
(Lucentis<SUP>&#174;</SUP>, a registered trademark of Genentech, Inc./Roche), an
anti-angiogenic agent approved for use in wet AMD. VIEW 1 is being conducted in
North America and VIEW 2 is being conducted in Europe, Asia Pacific, Japan, and
Latin America. The VIEW 1 and VIEW 2 trials are both evaluating VEGF Trap-Eye
doses of 0.5 mg and 2.0 mg at dosing intervals of four weeks and 2.0 mg at a
dosing interval of eight weeks (after three monthly doses) compared with
ranibizumab dosed according to its U.S. label, which specifies doses of 0.5 mg
administered every four weeks over the first year. As-needed dosing (PRN) with
both agents will be evaluated in the second year of the studies. We and Bayer
Healthcare expect to complete enrollment of the VIEW 1 and VIEW 2 trials in 2009
and initial data are expected in late 2010.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We and
Bayer HealthCare have conducted a Phase 2 study in wet AMD which demonstrated
that patients treated with VEGF Trap-Eye achieved durable improvements in visual
acuity and retinal thickness for up to one year. Study results were reported at
the 2008 annual meeting of the Retina Society.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In this
double-masked Phase 2 trial, known as CLEAR-IT 2, 157 patients were initially
treated for 3 months with VEGF Trap-Eye: two groups received monthly doses of
0.5 or 2.0 mg (at weeks 0, 4, 8, and 12) and three groups received quarterly
doses of 0.5, 2.0, or 4.0 mg (at baseline and week 12). Following the initial
3-month fixed-dosing phase, patients continued to receive VEGF Trap-Eye at the
same dose on a PRN dosing schedule through one year, based upon the physician
assessment of the need for re-treatment in accordance with pre-specified
criteria.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Patients
receiving monthly doses of VEGF Trap-Eye of either 2.0 or 0.5 milligrams (mg)
for 12 weeks followed by PRN dosing achieved mean improvements in visual acuity
versus baseline of 9.0 letters (p&lt;0.0001 versus baseline) and 5.4 letters
(p&lt;0.085 versus baseline), respectively, at the end of one year. The
proportion of patients with vision of 20/40 or better (part of the legal minimum
requirement for an unrestricted driver's license in the U.S.) increased from 23%
at baseline to 45% at week 52 in patients initially treated with 2.0 mg monthly
and from 16% at baseline to 47% at week 52 in patients initially treated with
0.5 mg monthly. Patients receiving monthly doses of VEGF Trap-Eye of either 2.0
or 0.5 mg also achieved mean decreases in retinal thickness versus baseline of
143 microns (p&lt;0.0001 versus baseline) and 125 microns (p&lt;0.0001 versus
baseline) at week 52, respectively.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>13</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>After
week 12 to week 52 in the PRN dosing period, patients initially dosed on a 2.0
mg monthly schedule received, on average, only 1.6 additional injections and
those initially dosed on a 0.5 mg monthly schedule received, on average, 2.5
additional injections.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>While PRN
dosing following a fixed quarterly dosing regimen (with dosing at baseline and
week 12) also yielded improvements in visual acuity and retinal thickness versus
baseline at week 52, the results generally were not as robust as those obtained
with initial fixed monthly dosing.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>All
patients who completed the one year CLEAR-IT 2 study were eligible to
participate in an extension stage of the study. Eighteen month results of the
extension stage are scheduled to be presented on May 4, 2009 at the 2009
Association for Research in Vision and Ophthalmology (ARVO) meeting. After
receiving VEGF Trap-Eye for one year, the 117 patients who elected to enter the
extension stage were dosed on a 2.0 mg PRN basis, irrespective of the dose at
which they were treated earlier in the study. On a combined basis, for these 117
patients, the mean gain in visual acuity was 7.3 letters (</FONT><I><FONT face=serif size=2>p</FONT></I><FONT face=serif size=2>&lt;0.0001 versus
baseline) at the 3-month primary endpoint of the original Phase 2 study, 8.4
letters (</FONT><I><FONT face=serif size=2>p</FONT></I><FONT face=serif size=2>&lt;0.0001 versus baseline) at one year, and 7.1 letters (</FONT><I><FONT face=serif size=2>p</FONT></I><FONT face=serif size=2>&lt;0.0001 versus
baseline) at month 6 of the extension stage. Thus, after 18 months of dosing
with VEGF Trap-Eye in the Phase 2 study, patients continued to maintain a highly
significant improvement in visual acuity versus baseline, while receiving, on
average, only 3.5 injections over the 15-month PRN dosing phase that extended
from month 3 to month 18.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Among all
the patients in the Phase 2 wet AMD study, VEGF Trap-Eye was generally well
tolerated and there were no drug-related serious adverse events. There was one
reported case of culture-negative endophthalmitis/uveitis in the study eye and
two arterial thrombotic events; these were deemed not to be drug-related. Three
deaths were reported&#151;one patient with pancreatic cancer, one patient with
squamous cell carcinoma of the lung, and one patient with pulmonary hypertension
(a pre-existing condition). The most common adverse events were those typically
associated with intravitreal injections and included conjunctival hemorrhage at
the injection site and transient increased intraocular pressure following an
injection.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
recently initiated Phase 2 DME study, known as the DA VINCI study, is a
double-masked, randomized, controlled trial that is evaluating four different
VEGF Trap-Eye regimens versus laser treatment. The study is expected to complete
enrollment of approximately 200 patients in the U.S., Canada, European Union,
and Australia by the end of 2009. The patients in the study will be treated for
52 weeks followed by six additional months of safety evaluation. The primary
efficacy endpoint is the change in best corrected visual acuity (BCVA) from
baseline to week 24.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Collaboration with Bayer
HealthCare</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
October 2006, we entered into a collaboration agreement with Bayer HealthCare
for the global development and commercialization outside the United States of
VEGF Trap-Eye. Under the agreement, we and Bayer HealthCare will collaborate on,
and share the costs of, the development of VEGF Trap-Eye through an integrated
global plan that encompasses wet AMD, DME, and other diseases and disorders.
Bayer HealthCare will market VEGF Trap-Eye outside the United States, where the
companies will share equally in profits from any future sales of VEGF Trap-Eye.
If VEGF Trap-Eye is granted marketing authorization in a major market country
outside the United States, we will be obligated to reimburse Bayer HealthCare
for 50% of the development costs that it has incurred under the agreement from
our share of the collaboration profits. Within the United States, we retain
exclusive commercialization rights to VEGF Trap-Eye and are entitled to all
profits from any such sales. We received an up-front payment of $75.0 million
from Bayer HealthCare. In 2007, we received a $20.0 million milestone payment
from Bayer HealthCare following dosing of the first patient in the Phase 3 study
of VEGF Trap-Eye in wet AMD, and can earn up to $90 million in additional
development and regulatory milestones related to the development of VEGF
Trap-Eye and marketing approvals in major market countries outside the United
States. We can also earn up to $135 million in sales milestones if total annual
sales of VEGF Trap-Eye outside the United States achieve certain specified
levels starting at $200 million.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>14</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><FONT face=serif size=2><STRONG><EM>3.
ARCALYST</EM></STRONG><SUP>&#174;</SUP><STRONG><EM></EM></STRONG></FONT> <FONT face=serif size=2><STRONG><EM>(rilonacept) &#150; Inflammatory
Diseases</EM></STRONG></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
evaluating ARCALYST in gout, a disease where as in CAPS, IL-1 may play an
important role in pain and inflammation. In September 2008, we announced the
results of a Phase 2 study which evaluated the efficacy and safety of ARCALYST
versus placebo in the prevention of gout flares induced by the initiation of
urate-lowering drug therapy that is used to control gout. In this 83-patient,
double-blind, placebo-controlled study, the mean number of flares per patient
over the first 12 weeks of urate-lowering therapy was 0.79 with placebo and 0.15
with ARCALYST (p=0.0011), an 81% reduction. This was the primary endpoint of the
study. All secondary endpoints also were met with statistical significance. In
the first 12 weeks of treatment, 45.2% of patients treated with placebo
experienced a gout flare and, of those, 47.4% had more than one flare. Among
patients treated with ARCALYST, only 14.6% experienced a gout flare (p=0.0037
versus placebo) and none had more than one flare. Injection-site reaction was
the most commonly reported adverse event with ARCALYST and no serious
drug-related adverse events were reported.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Gout is
characterized by high blood levels of uric acid, a bodily waste product normally
excreted by the kidneys. The uric acid can form crystals in the joints of the
toes, ankles, knees, wrists, fingers, and elbows. Chronic treatment with uric
acid-lowering medicines, such as allopurinol, is prescribed to eliminate the
uric acid crystals and prevent reformation. During the first months of
allopurinol therapy, while uric acid blood levels are being reduced, the break
up of the uric acid crystals can result in stimulation of inflammatory
mediators, including IL-1, resulting in acute flares of joint pain and
inflammation. These painful flares generally persist for at least five
days.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>During
the first quarter of 2009, we initiated a Phase 3 clinical development program
with ARCALYST for the treatment of gout. The program includes four clinical
trials, three of which are currently enrolling patients. Two Phase 3 clinical
trials (called PRE-SURGE 1 and PRE-SURGE 2) will evaluate ARCALYST versus
placebo for the prevention of gout flares in patients initiating urate-lowering
drug therapy. A third Phase 3 trial in acute gout (SURGE) will evaluate
treatment with ARCALYST alone versus ARCALYST in combination with a
non-steroidal anti-inflammatory drug (NSAID) versus an NSAID alone. The Phase 3
clinical development program also includes a separate placebo-controlled safety
study (RE-SURGE). We expect to report initial data from the Phase 3 program in
2010.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Under a
March 2003 collaboration agreement with Novartis Pharma AG, we retain the right
to elect to collaborate in the future development and commercialization of a
Novartis IL-1 antibody which is in clinical development. Following completion of
Phase 2 development and submission to us of a written report on the Novartis
IL-1 antibody, we have the right, in consideration for an opt-in payment, to
elect to co-develop and co-commercialize the Novartis IL-1 antibody in North
America. If we elect to exercise this right, we are responsible for paying 45%
of post-election North American development costs for the antibody product. In
return, we are entitled to co-promote the Novartis IL-1 antibody, and to receive
45% of net profits on sales of the antibody product, in North America. Under
certain circumstances, we are also entitled to receive royalties on sales of the
Novartis IL-1 antibody in Europe. Under the collaboration agreement, Novartis
has the right to elect to collaborate in the development and commercialization
of a second generation IL-1 Trap following completion of its Phase 2
development, should we decide to clinically develop such a second generation
product candidate. Novartis does not have any rights or options with respect to
ARCALYST.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>4. Monoclonal
Antibodies</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We and
sanofi-aventis are collaborating on the discovery, development, and
commercialization of fully human monoclonal antibodies generated using our
<EM>VelocImmune<SUP>&#174;</SUP></EM> technology. The first therapeutic antibodies to
enter clinical development under the collaboration are REGN88 and REGN475.
REGN88, an antibody to the interleukin-6 receptor (IL-6R) is being evaluated in
rheumatoid arthritis. REGN475, an antibody to Nerve Growth Factor (NGF) that
binds NGF selectively without cross-reacting with other members of the
neurotrophin family (such as neurotrophin-3, neurotrophin-4, and BDNF), is being
developed for the treatment of pain. In addition, a Phase 1 trial is in the
process of being initiated to evaluate REGN421, an antibody to Delta-like
ligand-4 (Dll4), in patients with advanced malignancies. Over the course of the
next several years, we and sanofi-aventis plan to advance an average of two to
three new fully human monoclonal antibodies into clinical development each
year.</FONT></P>
<P align=justify><B><U><FONT face=serif size=2>Research and Development
Technologies:</FONT></U></B><B><FONT face=serif size=2></FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>One way
that a cell communicates with other cells is by releasing specific signaling
proteins, either locally or into the bloodstream. These proteins have distinct
functions, and are classified into different &#147;families&#148; of molecules, such as
peptide hormones, growth factors, and cytokines. All of these secreted (or
signaling) proteins travel to and are recognized by another set of proteins,
called &#147;receptors,&#148; which reside on the surface of responding cells. These
secreted proteins impact many critical cellular and biological processes,
causing diverse effects ranging from the regulation of growth of particular cell
types, to inflammation mediated by white blood cells. Secreted proteins can at
times be overactive and thus result in a variety of diseases. In these disease
settings, blocking the action of secreted proteins can have clinical
benefit.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>15</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Regeneron scientists have developed two different technologies to design
protein therapeutics to block the action of specific secreted proteins. The
first technology, termed the &#147;Trap&#148; technology, was used to generate our first
approved product, ARCALYST<SUP>&#174;</SUP> (rilonacept), as well as aflibercept, and
VEGF Trap-Eye, all of which are in Phase 3 clinical trials. These novel &#147;Traps&#148;
are composed of fusions between two distinct receptor components and the
constant region of an antibody molecule called the &#147;Fc region&#148;, resulting in
high affinity product candidates. <I>VelociSuite</I> is our second technology
platform and it is used for discovering, developing, and producing fully human
monoclonal antibodies.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>VelociSuite<SUP>TM</SUP></FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2><I>VelociSuite</I> consists of <I>VelocImmune<SUP>&#174;</SUP>,
VelociGene<SUP>&#174;</SUP>, VelociMouse<SUP>&#174;</SUP>, and VelociMab<SUP>TM</SUP>.</I>
The <I>VelocImmune</I> mouse platform is utilized to produce fully human
monoclonal antibodies. <I>VelocImmune</I> was generated by exploiting our
<I>VelociGene</I> technology (see below), in a process in which six megabases of
mouse immune gene loci were replaced, or &#147;humanized,&#148; with corresponding human
immune gene loci. <I>VelocImmune</I> mice can be used to generate efficiently
fully human monoclonal antibodies to targets of therapeutic interest.
<I>VelocImmune</I> and our entire <I>VelociSuite</I> offer the potential to
increase the speed and efficiency through which human monoclonal antibody
therapeutics may be discovered and validated, thereby improving the overall
efficiency of our early stage drug development activities. We are utilizing the
<I>VelocImmune</I> technology to produce our next generation of drug candidates
for preclinical and clinical development.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
<I>VelociGene</I> platform allows custom and precise manipulation of very large
sequences of DNA to produce highly customized alterations of a specified target
gene, or genes, and accelerates the production of knock-out and transgenic
expression models without using either positive/negative selection or isogenic
DNA. In producing knock-out models, a color or fluorescent marker&nbsp;may
be&nbsp;substituted in place of the actual gene sequence, allowing for
high-resolution visualization of precisely where the gene is active in the body,
during normal body functioning, as well as in disease processes. For the
optimization of pre-clinical development and toxicology programs,
<I>VelociGene</I> offers the opportunity to humanize targets by replacing the
mouse gene with the human homolog. Thus, <I>VelociGene</I> allows scientists to
rapidly identify the physical and biological effects of deleting or
over-expressing the target gene, as well as to characterize and test potential
therapeutic molecules.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
<I>VelociMouse</I> technology platform allows for the direct and immediate
generation of genetically altered mice from embryonic stem cells (ES cells),
thereby avoiding the lengthy process involved in generating and breeding
knockout mice from chimeras. Mice generated through this method are normal and
healthy and exhibit a 100% germ-line transmission. Furthermore, Regeneron&#146;s
VelociMice are suitable for direct phenotyping or other studies. We have also
developed our <I>VelociMab</I> platform for the rapid screening of antibodies
and rapid&nbsp;generation of expression cell lines for our Traps and our
<I>VelocImmune</I> human monoclonal antibodies.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Antibody Collaboration with
sanofi-aventis</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
November 2007, we and sanofi-aventis entered into a global, strategic
collaboration to discover, develop, and commercialize fully human monoclonal
antibodies. The collaboration is governed by a Discovery and Preclinical
Development Agreement and a License and Collaboration Agreement. We received a
non-refundable, up-front payment of $85.0 million from sanofi-aventis under the
discovery agreement. In addition, sanofi-aventis is funding research at
Regeneron to identify and validate potential drug discovery targets and develop
fully human monoclonal antibodies against these targets. Sanofi-aventis funded
approximately $75 million of research from the collaboration&#146;s inception through
December 31, 2008 and will fund up to $100 million per year in 2009 through
2012. Sanofi-aventis also has an option to extend the discovery program for up
to an additional three years for further antibody development and preclinical
activities. We will lead the design and conduct of research activities,
including target identification and validation, antibody development, research
and preclinical activities through filing of an Investigational New Drug
Application, toxicology studies, and manufacture of preclinical and clinical
supplies.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>16</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For each
drug candidate identified under the discovery agreement, sanofi-aventis has the
option to license rights to the candidate under the license agreement. If it
elects to do so, sanofi-aventis will co-develop the drug candidate with us
through product approval. Development costs will be shared between the
companies, with sanofi-aventis generally funding drug candidate development
costs up front. We are generally responsible for reimbursing sanofi-aventis for
half of the total development costs for all collaboration products from our
share of profits from commercialization of collaboration products to the extent
they are sufficient for this purpose. Sanofi-aventis will lead commercialization
activities for products developed under the license agreement, subject to our
right to co-promote such products. The parties will equally share profits and
losses from sales within the United States. The parties will share profits
outside the United States on a sliding scale based on sales starting at 65%
(sanofi-aventis)/35% (us) and ending at 55% (sanofi-aventis)/45% (us), and will
share losses outside the United States at 55% (sanofi-aventis)/45% (us). In
addition to profit sharing, we are entitled to receive up to $250 million in
sales milestone payments, with milestone payments commencing after aggregate
annual sales outside the United States exceed $1.0 billion on a rolling 12-month
basis.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In August
2008, we entered into an agreement with sanofi-aventis to use our
<I>VelociGene<SUP>&#174;</SUP></I> platform to supply sanofi-aventis with genetically
modified mammalian models of gene function and disease. Sanofi-aventis will pay
us a minimum of $21.5 million for the term of the agreement, which extends
through December 2012, for knock-out and transgenic models of gene function for
target genes identified by sanofi-aventis. Sanofi-aventis will use these models
for its internal research programs that are outside of the scope of our antibody
collaboration.</FONT></P>
<P align=justify><B><FONT face=serif size=2>License Agreement with
AstraZeneca</FONT></B> <FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
February 2007, we entered into a non-exclusive license agreement with
AstraZeneca UK Limited that allows AstraZeneca to utilize our <I>VelocImmune</I>
technology in its internal research programs to discover human monoclonal
antibodies. Under the terms of the agreement, AstraZeneca made $20.0 million
annual, non-refundable payments to us in February 2007, 2008, and 2009.
AstraZeneca is required to make up to three additional annual payments of $20.0
million, subject to its ability to terminate the agreement after making the next
additional payment or earlier if the technology does not meet minimum
performance criteria. We are entitled to receive a mid-single-digit royalty on
any future sales of antibody products discovered by AstraZeneca using our
<I>VelocImmune</I> technology.</FONT></P>
<P align=justify><B><FONT face=serif size=2>License Agreement with
Astellas</FONT></B> <FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In March
2007, we entered into a non-exclusive license agreement with Astellas Pharma
Inc. that allows Astellas to utilize our <I>VelocImmune</I> technology in its
internal research programs to discover human monoclonal antibodies. Under the
terms of the agreement, Astellas made two $20.0 million annual, non-refundable
payments to us, one in April 2007 and the other in June 2008. Astellas is
required to make up to four additional annual payments of $20.0 million, subject
to its ability to terminate the agreement after making the first two additional
payments or earlier if the technology does not meet minimum performance
criteria. We are entitled to receive a mid-single-digit royalty on any future
sales of antibody products discovered by Astellas using our</FONT> <I><FONT face=serif size=2>VelocImmune</FONT></I> <FONT face=serif size=2>technology.</FONT></P>
<P align=justify><FONT face=serif size=2><STRONG>Academic</STRONG>
<STRONG><EM>VelocImmune</EM></STRONG><SUP>&#174;</SUP><STRONG><EM></EM></STRONG></FONT>
<FONT face=serif size=2><STRONG>Investigators&#146; Program</STRONG></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
September 2008, we entered into an agreement that will provide researchers at
Columbia University Medical Center with access to our <I>VelocImmune</I>
technology platform. In March 2009, we entered into a similar agreement with The
University of Texas Southwestern Medical Center at Dallas. Under the agreements,
scientists at these academic institutions will use <I>VelocImmune</I> mice to
generate antibodies against their research targets and will conduct research to
discover potential human therapeutics based on the antibodies. We have an
exclusive option to license the antibodies for development and commercialization
as therapeutic or diagnostic products and will pay&nbsp;to the appropriate
institution&nbsp;a low single-digit royalty on ensuing product sales.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>17</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>National Institutes of Health
Grant</FONT></B><FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
September 2006, we were awarded a five-year grant from the National Institutes
of Health (NIH) as part of the NIH&#146;s Knockout Mouse Project. The goal of the
Knockout Mouse Project is to build a comprehensive and broadly available
resource of knockout mice to accelerate the understanding of gene function and
human diseases. We are using our <I>VelociGene</I><SUP>&#174;</SUP> technology to
take aim at 3,500 of the most difficult genes to target and which are not
currently the focus of other large-scale knockout mouse programs. We also agreed
to grant a limited license to a consortium of research institutions, the other
major participants in the Knockout Mouse Project, to use components of
our</FONT> <I><FONT face=serif size=2>VelociGene</FONT></I> <FONT face=serif size=2>technology in the Knockout Mouse Project. We are generating a collection
of targeting vectors and targeted mouse ES cells which can be used to produce
knockout mice. These materials are available to academic researchers without
charge. We will receive a fee for each targeted ES cell line or targeting
construct made by us or the research consortium and transferred to commercial
entities.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Under the
NIH grant, as amended in September 2008, we are entitled to receive a minimum of
$24.5 million over the five-year period beginning September 2006, including $1.5
million to optimize our existing C57BL/6 ES cell line and its proprietary growth
medium, both of which are being supplied to the research consortium for its use
in the Knockout Mouse Project. We have the right to use, for any purpose, all
materials generated by us and the research consortium.</FONT></P>
<P align=justify><B><U><FONT face=serif size=2>Research
Programs</FONT></U></B><B><FONT face=serif size=2>:</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>Oncology and
Angiogenesis</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In many
clinical settings, positively or negatively regulating blood vessel growth could
have important therapeutic benefits, as could the repair of damaged and leaky
vessels. VEGF was the first growth factor shown to be specific for blood
vessels, by virtue of having its receptor specifically expressed on blood vessel
cells. In 1994, we discovered a second family of angiogenic growth factors,
termed angiopoietins, and we have received patents covering members of this
family. Angiopoietins include naturally occurring positive and negative
regulators of angiogenesis, as described in numerous scientific manuscripts
published by our scientists and their collaborators. Angiopoietins are being
evaluated in preclinical research by us and our academic collaborators. Our
preclinical studies have revealed that VEGF and angiopoietins normally function
in a coordinated and collaborative manner during blood vessel growth.
Manipulation of both VEGF and angiopoietins seems to be of value in either
promoting or blocking vessel growth. We have research programs focusing on
several targets in the areas of oncology and angiogenesis.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Tumors
depend on the growth of new blood vessels (a process called &#147;angiogenesis&#148;) to
support their continued growth. Therapies that block tumor angiogenesis,
specifically those that block VEGF, the key initiator of tumor angiogenesis,
recently have been validated in human cancer patients. However, anti-VEGF
approaches do not work in all patients, and many tumors can become resistant to
such therapies.</FONT><I><FONT face=serif size=2></FONT></I> <FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
December 21, 2006 issue of the journal</FONT> <I><FONT face=serif size=2>Nature,</FONT></I> <FONT face=serif size=2>we reported data from a
preclinical study demonstrating that blocking an important cell signaling
molecule, known as Delta-like ligand 4 (Dll4), inhibited the growth of
experimental tumors by interfering with their ability to produce a functional
blood supply. The inhibition of tumor growth was seen in a variety of tumor
types, including those that were resistant to blockade of VEGF, suggesting a
novel anti-angiogenesis therapeutic approach. We are in the process of
initiating Phase 1 clinical development of a fully human monoclonal antibody to
Dll4 that was discovered using our <EM>VelocImmune</EM><SUP>&#174;</SUP>
technology.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>18</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>Metabolic and Related Diseases
</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Food
intake and metabolism are regulated by complex interactions between diverse
neural and hormonal signals that serve to maintain an optimal balance between
energy intake, storage, and utilization. The hypothalamus, a small area at the
base of the brain, is critically involved in integrating peripheral signals
which reflect nutritional status and neural outputs which regulate appetite,
food seeking behaviors, and energy expenditure. Metabolic disorders, such as
type 2 diabetes, reflect a dysregulation in the systems which ordinarily tightly
couple energy intake to energy expenditure. Our preclinical research program in
this area encompasses the study of peripheral (hormonal) regulators of food
intake and metabolism in health and disease. We have identified several targets
in these therapeutic areas and are evaluating lead monoclonal antibodies in
relevant preclinical models.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Muscle Diseases and
Disorders</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Muscle
atrophy occurs in many neuromuscular diseases and also when muscle is unused, as
often occurs during prolonged hospital stays and during convalescence.
Currently, physicians have few options to treat subjects with muscle atrophy or
other muscle conditions which afflict millions of people globally. Thus, a
treatment that has beneficial effects on skeletal muscle could have significant
clinical benefit. Our muscle research program is currently focused on conducting
<EM>in vivo</EM> and <EM>in vitro</EM> experiments with the objective of
demonstrating and further understanding the molecular pathways involved in
muscle atrophy and hypertrophy, and discovering therapeutic candidates that can
modulate these pathways. We have several molecules in late stage research and
are evaluating them for possible further development.</FONT></P>
<P align=center><FONT face=serif size=2>19</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>Other Therapeutic
Areas</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We also
have research programs focusing on ophthalmology, inflammatory and immune
diseases, bone and cartilage, pain, and cardiovascular diseases.</FONT></P>
<P align=justify><B><FONT face=serif size=2>General</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Developing and commercializing new medicines entails significant risk and
expense. Since inception we have not generated any significant sales or profits
from the commercialization of ARCALYST or any of our other product candidates.
Before significant revenues from the commercialization of ARCALYST or our other
product candidates can be realized, we (or our collaborators) must overcome a
number of hurdles which include successfully completing research and development
and obtaining regulatory approval from the FDA and regulatory authorities in
other countries. In addition, the biotechnology and pharmaceutical industries
are rapidly evolving and highly competitive, and new developments may render our
products and technologies uncompetitive or obsolete.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>From
inception on January 8, 1988 through March 31, 2009, we had a cumulative loss of
$893.4 million. In the absence of significant revenues from the
commercialization of ARCALYST or our other product candidates or other sources,
the amount, timing, nature, and source of which cannot be predicted, our losses
will continue as we conduct our research and development activities. We expect
to incur substantial losses over the next several years as we continue the
clinical development of VEGF Trap-Eye and ARCALYST in other indications; advance
new product candidates into clinical development from our existing research
programs utilizing our technology for&nbsp;discovering fully human monoclonal
antibodies; continue our research and development programs; and commercialize
additional product candidates that receive regulatory approval, if any. Also,
our activities may expand over time and require additional resources, and we
expect our operating losses to be substantial over at least the next several
years. Our losses may fluctuate from quarter to quarter and will depend on,
among other factors, the progress of our research and development efforts, the
timing of certain expenses, and the amount and timing of payments that we
receive from collaborators.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
planning, execution, and results of our clinical programs are significant
factors that can affect our operating and financial results. In our clinical
programs, key events to date in 2009 and plans over the next 12 months are as
follows:</FONT></P>
<DIV align=center>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="95%" border=0>

  <TR vAlign=bottom>
    <TD align=left width="22%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=left width="41%">&nbsp;</TD>
    <TD align=left width="1%"></TD>
    <TD align=left width="34%"><B><FONT face=serif size=2>2009-10
      Plans</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="22%"><B><FONT face=serif size=2>Clinical Program</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="41%"><B><FONT face=serif size=2>2009 Events to Date</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="34%"><B><FONT face=serif size=2>(next 12 months)</FONT></B></TD></TR>
  <TR>
    <TD vAlign=top align=left width="22%">
      <P align=justify><FONT face=serif size=2>ARCALYST<SUP>&#174;</SUP></FONT><FONT face=serif size=2><SUP><BR></SUP></FONT><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (rilonacept;
      also<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; known as IL-1
    Trap)</FONT></P></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="41%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 1pt; MARGIN-LEFT: 16px">
        <LI><FONT face=serif size=2>Initiated patient enrollment in the Phase 3
        program evaluating ARCALYST in the prevention of gout flares associated
        with the initiation of urate-lowering drug therapy and in the treatment
        of acute gout attacks</FONT></LI></UL></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="34%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 1pt; MARGIN-LEFT: 16px">
        <LI><FONT face=serif size=2>Continue enrollment in the Phase 3 program
        in gout</FONT></LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="22%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="41%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="34%"></TD></TR>
  <TR>
    <TD vAlign=top align=left width="22%">
      <P align=justify><FONT face=serif size=2>Aflibercept&nbsp;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (VEGF
      Trap &#150;<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oncology)</FONT></P></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="41%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 1pt; MARGIN-LEFT: 16px">
        <LI><FONT face=serif size=2>Initiated a Phase 2 1st-line study in
        metastatic colorectal cancer in combination with chemotherapy</FONT>
        <LI><FONT face=serif size=2>Achieved approximately 50% enrollment in
        each of the Phase 3 studies</FONT></LI></UL></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="34%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 1pt; MARGIN-LEFT: 16px">
        <LI><FONT face=serif size=2>Report results of a Phase 2 single-agent
        study in SMA</FONT>
        <LI><FONT face=serif size=2>Continue enrollment of the four Phase 3
        studies</FONT></LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="22%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="41%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="34%"></TD></TR>
  <TR>
    <TD vAlign=top align=left width="22%">
      <P align=justify><FONT face=serif size=2>VEGF
      Trap-Eye<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (intravitreal
      injection)</FONT></P></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="41%"></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="34%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 1pt; MARGIN-LEFT: 16px">
        <LI><FONT face=serif size=2>Complete enrollment in VIEW 1 and VIEW 2
        trials</FONT>
        <LI><FONT face=serif size=2>Continue enrolling patients in the Phase 2
        DME trial</FONT>
        <LI>Initiate a Phase 3 CRVO program</LI></UL></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="22%"><B><FONT face=serif size=2>&nbsp;</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="41%"><B><FONT face=serif size=2>&nbsp;</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=left width="34%"><B><FONT face=serif size=2>&nbsp;</FONT></B></TD></TR>
  <TR>
    <TD vAlign=top align=left width="22%">
      <P align=justify><FONT face=serif size=2>Monoclonal<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Antibodies</FONT><FONT face=serif size=2></FONT></P></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="41%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 1pt; MARGIN-LEFT: 16px">
        <LI><FONT face=serif size=2>Initiated a Phase 1 trial for REGN475
        (anti-NGF) in healthy volunteers</FONT></LI></UL></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="34%">
      <UL style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 1pt; MARGIN-LEFT: 16px">
        <LI><FONT face=serif size=2>Initiate a Phase 1 trial for REGN421(anti
        Dll4) in oncology</FONT>
        <LI><FONT face=serif size=2>Report data from a Phase 1 trial of REGN88
        (anti-IL-6R) in rheumatoid arthritis</FONT>
        <LI><FONT face=serif size=2>Initiate multiple Phase 2 trials for REGN475
        in pain indications</FONT>
        <LI><FONT face=serif size=2>Advance additional antibody candidate(s)
        into clinical development&nbsp;</FONT></LI></UL></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="22%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="41%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="34%"></TD></TR></TABLE></DIV><BR>
<P align=center><FONT face=serif size=2>20</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<DIV align=center></DIV>
<P align=justify><B><FONT face=serif size=2>Results of Operations</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>Three Months Ended March 31, 2009
and 2008</FONT></I></B></P>
<P align=justify><I><FONT face=serif size=2>Net Loss:</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Regeneron
reported a net loss of $17.5 million, or $0.22 per share (basic and diluted),
for the first quarter of 2009 compared to a net loss of $11.6 million, or $0.15
per share (basic and diluted), for the first quarter of 2008. The increase in
our net loss was principally due to higher research and development expenses, as
detailed below, partly offset by higher contract research and development
revenue in connection with our antibody collaboration with sanofi-aventis and
net product sales of ARCALYST<SUP>&#174;</SUP></FONT> <FONT face=serif size=2>(rilonacept) for the treatment of CAPS.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Revenues:</FONT></I></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Revenues for the three months ended
March 31, 2009 and 2008 consist of the following:</FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><B><I><FONT face=serif size=2>(In
      millions)</FONT></I></B>&nbsp;</TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=2><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=2><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#c0c0c0><FONT face=serif size=2>Contract research &amp; development revenue</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Sanofi-aventis</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>49.6</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>35.7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Bayer HealthCare</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>10.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>9.0</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Other</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>1.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>1.7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Total contract research &amp; development
    revenue</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>61.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>46.4</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face=serif size=2>Technology
      licensing revenue</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>10.0</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>10.0</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#c0c0c0><FONT face=serif size=2>Net product sales</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>3.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Total revenue</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face=serif size=2>75.0</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face=serif size=2>56.4</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The contract and research
development revenue we earn from sanofi-aventis, as detailed below, consists
primarily of reimbursement for research and development expenses and partly of
the recognition of revenue related to non-refundable up-front payments of $105.0
million related to the aflibercept collaboration and $85.0 million related to
the antibody collaboration.</FONT></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="20%"><B><FONT face=serif size=2>Sanofi-aventis Contract Research
      &amp; Development Revenue</FONT></B></TD>
    <TD noWrap align=left width="72%">&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="7%" colSpan=5><B><FONT face=serif size=2>Three months ended</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" colSpan=2><B><I><FONT face=serif size=2>(In millions)</FONT></I></B>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=5><B><FONT face=serif size=2>March 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" colSpan=2><FONT face=serif size=2>Aflibercept:</FONT></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=2><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=2><B><FONT face=serif size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Regeneron expense reimbursement</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>5.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>11.7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Recognition of deferred revenue related to up-front
    payments</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>2.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>2.1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Total aflibercept</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>7.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>13.8</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" colSpan=2><FONT face=serif size=2>Antibody:</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Regeneron expense reimbursement</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>38.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>19.3</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Recognition of deferred revenue related to up-front
    payment</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>2.6</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>2.6</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Recognition of revenue related to</FONT> <I><FONT face=serif size=2>VelociGene<SUP>&#174;</SUP></FONT></I> <FONT face=serif size=2>agreement</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>0.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Total antibody</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>41.7</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>21.9</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Total sanofi-aventis contract research &amp; development
      revenue</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>49.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>35.7</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>21</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><FONT size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Sanofi-aventis&#146; reimbursement of
Regeneron&#146;s aflibercept expenses decreased in the first quarter of 2009,
compared to the same period in 2008, primarily due to lower costs related to
manufacturing aflibercept clinical supplies. Recognition of deferred revenue
related to sanofi-aventis&#146; up-front aflibercept payments increased in the first
quarter of 2009 compared to the same period in 2008 due to shortening the
estimated performance period over which this deferred revenue is being
recognized, effective in the fourth quarter of 2008. As of March 31, 2009, $49.9
million of the original $105.0 million of up-front payments related to
aflibercept was deferred and will be recognized as revenue in future
periods.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In the first quarter
of 2009, sanofi-aventis&#146; reimbursement of Regeneron&#146;s antibody expenses
consisted of $22.7 million under the discovery agreement and $15.7 million of
development costs under the license agreement, compared to $15.1 million and
$4.2 million, respectively, in the first quarter of 2008. Higher sanofi-aventis&#146;
reimbursements in the first quarter of 2009 compared to the same period in 2008
were due to an increase in our research activities conducted under the discovery
agreement and increases in our development activities for REGN88, REGN421, and
REGN475 under the license agreement.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>Recognition of
deferred revenue under the antibody collaboration related to sanofi-aventis&#146;
$85.0 million up-front payment. As of March 31, 2009, $71.0 million of this
up-front payment was deferred and will be recognized as revenue in future
periods.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>As described above,
in August, 2008, we entered into a separate <I>VelociGene</I><SUP>&#174;</SUP>
agreement with sanofi-aventis. For the three months ended March 31, 2009, we
recognized $0.7 million of revenue related to this agreement.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>The contract
research and development revenue we earn from Bayer HealthCare, as detailed
below, consists partly of cost sharing of Regeneron VEGF Trap-Eye development
expenses and partly of recognition of revenue related to a non-refundable $75.0
million up-front payment and $20.0 million non-substantive milestone
payment.</FONT></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="66%" colSpan=2>&nbsp;</TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="31%" colSpan=5><B><FONT size=2>Three months
      ended</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT size=2>Bayer HealthCare Contract Research &amp;
      Development Revenue</FONT></B></TD>
    <TD noWrap align=left width="65%">&nbsp;</TD>
    <TD noWrap align=center width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="31%" colSpan=5><B><FONT size=2>March 31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="66%" colSpan=2><B><I><FONT size=2>(In
      millions)</FONT></I></B>&nbsp;</TD>
    <TD noWrap align=center width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="12%" colSpan=2><B><FONT size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="3%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="16%" colSpan=2><B><FONT size=2>2008</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="66%" bgColor=#c0c0c0 colSpan=2><FONT size=2>Cost-sharing of Regeneron VEGF Trap-Eye development
    expenses</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0><FONT size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=right width="9%" bgColor=#c0c0c0><FONT size=2>7.5</FONT></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0><FONT size=2>$</FONT></TD>
    <TD noWrap align=right width="13%" bgColor=#c0c0c0><FONT size=2>5.7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="66%" colSpan=2><FONT size=2>Recognition of deferred
      revenue related to up-front and milestone payments</FONT></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="9%"><FONT size=2>2.5</FONT></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="13%"><FONT size=2>3.3</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="66%" bgColor=#c0c0c0 colSpan=2>&nbsp;
      &nbsp;&nbsp;&nbsp;&nbsp; <FONT size=2>Total Bayer HealthCare contract
      research &amp; development revenue</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="3%" bgColor=#c0c0c0><FONT size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="9%" bgColor=#c0c0c0><FONT size=2>10.0</FONT></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="3%" bgColor=#c0c0c0><FONT size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="13%" bgColor=#c0c0c0><FONT size=2>9.0</FONT></TD></TR></TABLE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In the first quarter
of 2009, cost-sharing of Regeneron VEGF Trap-Eye development expenses increased,
compared to the same period in 2008, primarily due to higher clinical
development costs in connection with our VIEW 1 trial in wet AMD and Phase 2
trial in DME. Recognition of deferred revenue related to Bayer&#146;s up-front and
milestone payments decreased in the first quarter of 2009 compared to the same
period in 2008 due to an extension of the estimated performance period over
which this deferred revenue is being recognized, effective in the fourth quarter
of 2008. As of March 31, 2009, $64.2 million of the up-front licensing and
milestone payments was deferred and will be recognized as revenue in future
periods.</FONT></P>
<P align=justify><FONT size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Other contract research and
development revenue in the first quarter of 2009 and 2008 includes $1.5 million
and $1.1 million, respectively, in connection with our five-year grant from the
NIH, which we were awarded in September 2006 as part of the NIH&#146;s Knockout Mouse
Project.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>In connection with
our <I>VelocImmune</I><SUP>&#174;</SUP> license agreements with AstraZeneca and
Astellas, each of the $20.0 million annual, non-refundable payments are deferred
upon receipt and recognized as revenue ratably over approximately the ensuing
year of each agreement. In the first quarter of both 2009 and 2008, we
recognized $10.0 million of technology licensing revenue related to these
agreements.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2>For the three months
ended March 31, 2009, we recognized as revenue $3.9 million of
ARCALYST<SUP>&#174;</SUP></FONT> <FONT size=2>(rilonacept) net product sales for
which both the right of return no longer exists and rebates can be reasonably
estimated. At March 31, 2009, deferred revenue related to ARCALYST net product
sales totaled $4.2 million.</FONT></P>
<P align=center><FONT size=2>22</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><I><FONT face=serif size=2>Expenses:</FONT></I><FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Total
operating expenses increased to $94.2 million in the first quarter of 2009 from
$72.3 million in the same period of 2008. Our average headcount increased to 938
in the first quarter of 2009 from 714 in the same period of 2008 principally as
a result of our expanding research and development activities which are
primarily attributable to the sanofi-aventis antibody collaboration.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Operating
expenses in the first quarter of 2009 and 2008 include a total of $7.7 million
and $8.3 million, respectively, of non-cash compensation expense related to
employee stock option and restricted stock awards (Non-cash Compensation
Expense), as detailed below:</FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="95%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="17%" colSpan=14><B><FONT face=serif size=2>For the three months ended March 31,
      2009</FONT></B></TD></TR>
  <TR>
    <TD noWrap align=left width="82%" colSpan=2></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><STRONG>Expenses
      before</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>inclusion of Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Expenses</FONT></B></TD>
    <TD noWrap align=left width="81%">&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Expenses as</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><B><I><FONT face=serif size=2>(In millions)</FONT></I></B>&nbsp;</TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Reported</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Research and development</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>77.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>4.7</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>82.1</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face=serif size=2>Selling, general, and administrative</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>8.7</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>3.0</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>11.7</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Cost of goods sold</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>0.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>0.4</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2>&nbsp; &nbsp; &nbsp;&nbsp;
      <FONT face=serif size=2>Total operating expenses</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face=serif size=2>86.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face=serif size=2>7.7</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face=serif size=2>94.2</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR></TABLE></DIV><BR>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="95%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="17%" colSpan=14><B><FONT face=serif size=2>For the three months ended March 31,
      2008</FONT></B></TD></TR>
  <TR>
    <TD noWrap align=left width="82%" colSpan=2></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><STRONG>Expenses
      before</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>inclusion of Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Non-cash</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Expenses</FONT></B></TD>
    <TD noWrap align=left width="81%">&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Compensation</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Expenses as</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><B><I><FONT face=serif size=2>(In millions)</FONT></I></B>&nbsp;</TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Expense</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Reported</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Research and development</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>56.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>4.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>61.3</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face=serif size=2>Selling, general, and administrative</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>7.6</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>3.4</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>11.0</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Total operating expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>64.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>8.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>72.3</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR></TABLE></DIV><BR>
<P align=justify><I><FONT face=serif size=2>Research and Development
Expenses:</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Research
and development expenses increased to $82.1 million in the first quarter of 2009
from $61.3 million in the same period of 2008. The following table summarizes
the major categories of our research and development expenses for the three
months ended March 31, 2009 and 2008:</FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="95%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="17%" colSpan=14><B><FONT face=serif size=2>For the three months ended March
      31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Research and Development
      Expenses</FONT></B></TD>
    <TD noWrap align=left width="81%">&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Increase</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><B><I><FONT face=serif size=2>(In millions)</FONT></I></B>&nbsp;</TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>2008</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>(Decrease)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Payroll and benefits (1)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>22.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>19.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>3.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" colSpan=2><FONT face=serif size=2>Clinical
      trial expenses</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>19.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>8.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>10.8</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Clinical manufacturing costs (2)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>14.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>14.7</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>(0.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" colSpan=2><FONT face=serif size=2>Research and
      preclinical development costs</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>8.4</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>5.5</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>2.9</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Occupancy and other operating costs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>10.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>6.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>3.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" colSpan=2><FONT face=serif size=2>Cost-sharing
      of Bayer HealthCare VEGF</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trap-Eye development expenses
      (3)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>7.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>6.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>0.4</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="82%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total research and
      development</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face=serif size=2>82.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face=serif size=2>61.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face=serif size=2>20.8</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR></TABLE></DIV><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap><FONT face=serif size=2>(1)</FONT></TD>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top width="100%"><FONT face=serif size=2>Includes $4.0 million
      and $4.2 million of Non-cash Compensation Expense for the three months
      ended March 31, 2009 and 2008, respectively.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face=serif size=2>(2)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top width="100%"><FONT face=serif size=2>Represents the full
      cost of manufacturing drug for use in research, preclinical development,
      and clinical trials, including related payroll and benefits, Non-cash
      Compensation Expense, manufacturing materials and supplies, depreciation,
      and occupancy costs of our Rensselaer manufacturing facility. Includes
      $0.7 million of Non-cash Compensation Expense for both the three months
      ended March 31, 2009 and 2008.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face=serif size=2>(3)</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top width="100%"><FONT face=serif size=2>Under our
      collaboration with Bayer HealthCare, in periods when Bayer HealthCare
      incurs VEGF Trap-Eye development expenses, we also recognize, as
      additional research and development expense, the portion of Bayer
      HealthCare&#146;s VEGF Trap-Eye development expenses that we are obligated to
      reimburse.</FONT></TD></TR></TABLE>
<P align=center><FONT face=serif size=2>23</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Payroll
and benefits increased principally due to the increase in employee headcount, as
described above. Clinical trial expenses increased due primarily to higher costs
related to our clinical development programs for (i) VEGF Trap-Eye, including
our VIEW 1 trial in wet AMD and Phase 2 trial in DME, (ii) ARCALYST, related to
our Phase 3 clinical development program in gout, and (iii) monoclonal
antibodies, primarily related to REGN88 in rheumatoid arthritis. Clinical
manufacturing costs decreased due to lower costs related to manufacturing
aflibercept clinical supplies, partially offset by higher costs related to
manufacturing clinical supplies of ARCALYST and monoclonal antibodies, including
REGN88. Research and preclinical development costs increased primarily due to
higher costs associated with our antibody programs. Occupancy and other
operating costs increased principally in connection with our higher headcount,
expanded research and development activities, and new operating lease for our
Tarrytown, New York facilities, which commenced in June 2008. Cost-sharing of
Bayer HealthCare&#146;s VEGF Trap-Eye development expenses slightly increased
primarily due to higher costs in connection with the VIEW 2 trial in wet AMD,
which is being conducted by Bayer HealthCare.</FONT><FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We budget
our research and development costs by expense category, rather than by project.
We also prepare estimates of research and development costs for projects in
clinical development, which include direct costs and allocations of certain
costs such as indirect labor, Non-cash Compensation Expense, and manufacturing
and other costs related to activities that benefit multiple projects, and, under
our collaboration with Bayer HealthCare, the portion of Bayer HealthCare&#146;s VEGF
Trap-Eye development expenses that we are obligated to reimburse. Our estimates
of research and development costs for clinical development programs (including
ARCALYST for the treatment of CAPS prior to receipt of marketing approval from
the FDA in February 2008) are shown below:</FONT></P>
<DIV align=center>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="95%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Project Costs</FONT></B></TD>
    <TD noWrap align=left width="81%">&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="17%" colSpan=14><B><FONT face=serif size=2>For the three months ended March
      31,</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>Increase</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><B><I><FONT face=serif size=2>(In millions)</FONT></I></B>&nbsp;</TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>2009</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>2008</FONT></B>&nbsp;</TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face=serif size=2>(Decrease)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>ARCALYST</FONT><SUP><FONT face=serif size=2>&#174;</FONT></SUP> <FONT face=serif size=2>(rilonacept)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>17.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>8.0</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>9.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face=serif size=2>Aflibercept</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>4.2</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>10.1</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>(5.9</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>VEGF Trap-Eye</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>20.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>16.6</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>4.2</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face=serif size=2>REGN88</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>9.0</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>3.8</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>5.2</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>REGN421 and REGN475</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>4.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>4.9</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" colSpan=2><FONT face=serif size=2>Other
      research programs &amp; unallocated costs</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>25.3</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>22.8</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%"><FONT face=serif size=2>2.5</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="82%" bgColor=#c0c0c0 colSpan=2>&nbsp;
      &nbsp;&nbsp;&nbsp;&nbsp; <FONT face=serif size=2>Total research and
      development expenses</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>82.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>61.3</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>20.8</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR></TABLE></DIV>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Drug
development and approval in the United States is a multi-step process regulated
by the FDA. The process begins with discovery and preclinical evaluation,
leading up to the submission of an IND to the FDA which, if successful, allows
the opportunity for study in humans, or clinical study, of the potential new
drug. Clinical development typically involves three phases of study: Phase 1, 2,
and 3. The most significant costs in clinical development are in Phase 3
clinical trials, as they tend to be the longest and largest studies in the drug
development process. Following successful completion of Phase 3 clinical trials
for a biological product, a biologics license application (or BLA) must be
submitted to, and accepted by, the FDA, and the FDA must approve the BLA prior
to commercialization of the drug. It is not uncommon for the FDA to request
additional data following its review of a BLA, which can significantly increase
the drug development timeline and expenses. We may elect either on our own, or
at the request of the FDA, to conduct further studies that are referred to as
Phase 3B and 4 studies. Phase 3B studies are initiated and either completed or
substantially completed while the BLA is under FDA review. These studies are
conducted under an IND. Phase 4 studies, also referred to as post-marketing
studies, are studies that are initiated and conducted after the FDA has approved
a product for marketing. In addition, as discovery research, preclinical
development, and clinical programs progress, opportunities to expand development
of drug candidates into new disease indications can emerge. We may elect to add
such new disease indications to our development efforts (with the approval of
our collaborator for joint development programs), thereby extending the period
in which we will be developing a product. For example, we, and our collaborators
where applicable, continue to explore further development of ARCALYST,
aflibercept, and VEGF Trap-Eye in different disease indications.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There are
numerous uncertainties associated with drug development, including uncertainties
related to safety and efficacy data from each phase of drug development,
uncertainties related to the enrollment and performance of clinical trials,
changes in regulatory requirements, changes in the competitive landscape
affecting a product candidate, and other risks and uncertainties described in
Item 1A, &#147;Risk Factors&#148; under &#147;Risks Related to ARCALYST<SUP>&#174;</SUP>
(rilonacept) and the Development of Our Product Candidates,&#148; &#147;Regulatory and
Litigation Risks,&#148; and &#147;Risks Related to Commercialization of Products.&#148; The
lengthy process of seeking FDA approvals, and subsequent compliance with
applicable statutes and regulations, require the expenditure of substantial
resources. Any failure by us to obtain, or delay in obtaining, regulatory
approvals could materially adversely affect our business.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>24</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>For these
reasons and due to the variability in the costs necessary to develop a product
and the uncertainties related to future indications to be studied, the estimated
cost and scope of the projects, and our ultimate ability to obtain governmental
approval for commercialization, accurate and meaningful estimates of the total
cost to bring our product candidates to market are not available. Similarly, we
are currently unable to reasonably estimate if our product candidates will
generate material product revenues and net cash inflows. In the first quarter of
2008, we received FDA approval for ARCALYST<SUP>&#174;</SUP> (rilonacept) for the
treatment of CAPS, a group of rare, inherited auto-inflammatory diseases. These
rare diseases affect a very small group of people. As a result, we can not
predict whether the commercialization of ARCALYST in CAPS will result in a
significant net cash benefit to us.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Selling, General, and Administrative
Expenses:</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Selling,
general, and administrative expenses increased to $11.7 million in the first
quarter of 2009 from $11.0 million in the same period of 2008 due to (i) higher
selling expenses related to ARCALYST, (ii) higher compensation expense due
primarily to increases in administrative headcount to support our expanded
research and development activities, and (iii) higher administrative
facility-related costs arising principally in connection with our higher
headcount and the new operating lease for our Tarrytown, New York facilities,
which commenced in June 2008.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Cost of Goods Sold:</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In the
third quarter of 2008, we began recognizing revenue and cost of goods sold from
product sales of ARCALYST. We began capitalizing inventory costs associated with
commercial supplies of ARCALYST subsequent to receipt of marketing approval from
the FDA in February 2008. Costs for manufacturing supplies of ARCALYST prior to
receipt of FDA approval were recognized as research and development expenses in
the period that the costs were incurred. Therefore, these costs are not being
included in cost of goods sold when revenue is recognized from the sale of those
supplies of ARCALYST. Cost of goods sold for the first quarter of 2009 was $0.4
million and consisted primarily of royalty and other period costs related to
ARCALYST commercial supplies.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Other Income and
Expense:</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Investment income decreased to $1.8 million in the first quarter of 2009
from $7.3 million in the comparable quarter of 2008. The decrease in investment
income was due to lower yields on, and lower balances of, cash and marketable
securities in the first quarter of 2009 compared to the same quarter of 2008.
Interest expense was $3.0 million in the first quarter of 2008 and related to
$200.0 million of formerly outstanding 5.5% Convertible Senior Subordinated
Notes which we either repurchased or repaid in full during 2008.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Liquidity and Capital
Resources</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Since our
inception in 1988, we have financed our operations primarily through offerings
of our equity securities, a private placement of convertible debt (which was
repurchased or repaid in 2008), purchases of our equity securities by our
collaborators, including sanofi-aventis, revenue earned under our past and
present research and development agreements, including our agreements with
sanofi-aventis and Bayer HealthCare, our past contract manufacturing agreements,
and our technology licensing agreements, ARCALYST product revenue, and
investment income.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Three months ended March 31, 2009
and 2008</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At March
31, 2009, we had $496.0 million in cash, cash equivalents, restricted cash, and
marketable securities compared with $527.5 million at December 31, 2008. In
February 2009, we received a $20.0 million annual, non-refundable payment in
connection with our non-exclusive license agreement with AstraZeneca.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>25</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><I><FONT face=serif size=2>Cash Used in
Operations:</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Net cash
used in operations was $10.2 million in the first quarter of 2009 compared to
$17.9 million in the first quarter of 2008. Our net losses of $17.5 million in
the first quarter of 2009 and $11.6 million in the first quarter of 2008
included $7.7 million and $8.3 million, respectively, of Non-cash Compensation
Expense.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At March
31, 2009, accounts receivable increased by $13.0 million, compared to
end-of-year 2008, primarily due to a higher receivable balance related to our
antibody collaboration with sanofi-aventis. Also, prepaid expenses and other
assets increased by $8.6 million at March 31, 2009 compared to end-of-year 2008
due primarily to higher prepaid clinical trial costs. At March 31, 2009,
accounts payable, accrued expenses, and other liabilities increased by $15.3
million compared to end-of-year 2008. The increase was due primarily to higher
liabilities for clinical trial and payroll costs, and capital expenditures,
primarily for tenant improvements and related costs in connection with our new
leased facilities in Tarrytown, New York, partially offset by a lower
cost-sharing payment due to Bayer HealthCare in connection with the companies&#146;
VEGF Trap-Eye collaboration.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At March
31, 2008, accounts receivable increased by $14.6 million, compared to
end-of-year 2007, primarily due to higher receivable balances related to our
collaborations with sanofi-aventis. Accounts payable, accrued expenses, and
other liabilities decreased by $7.6 million at March 31, 2008, compared to
end-of-year 2007, due primarily to reductions in accrued payroll costs and the
amount of the cost-sharing payment due to Bayer HealthCare in connection with
the companies&#146; VEGF Trap-Eye collaboration.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Cash (Used in) Provided by Investing
Activities:</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Net cash
used in investing activities was $39.5 million in the first quarter of 2009
compared to net cash provided by investing activities of $37.9 million in the
same period of 2008, due primarily to an increase in purchases of marketable
securities net of sales or maturities. In the first quarter of 2009, purchases
exceeded sales or maturities of marketable securities by $17.6 million, whereas
in the first quarter of 2008, sales or maturities exceeded purchases of
marketable securities by $41.0 million. In addition, cash used for capital
expenditures totaled $21.9 million in the first three months of 2009, primarily
for tenant improvements and related costs in connection with our new leased
facilities in Tarrytown.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Cash Provided by Financing
Activities:</FONT></I></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Cash
provided by financing activities decreased to $1.0 million in the first quarter
of 2009 from $1.9 million in the same period in 2008 due to a decrease in
issuances of Common Stock in connection with exercises of employee stock
options.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Fair Value of Marketable
Securities:</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>At March
31, 2009 and December 31, 2008, we held marketable securities whose aggregate
fair value totaled $295.2 million and $278.0 million, respectively. The
composition of our portfolio of marketable securities on these dates was as
follows:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2>&nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=5><B><FONT face=serif size=2>March 31, 2009</FONT></B> &nbsp;</TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=5><B><FONT face=serif size=2>December 31, 2008</FONT></B>
  &nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face=serif size=2>Investment type</FONT></B></TD>
    <TD noWrap align=left width="83%">&nbsp;</TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=2><B><FONT face=serif size=2>Fair Value</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=2><B><FONT face=serif size=2>Percent</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=2><B><FONT face=serif size=2>Fair Value</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=2><B><FONT face=serif size=2>Percent</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>U.S. Treasury securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>131.0</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>44</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>113.9</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>41</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face=serif size=2>U.S.
      government agency securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>59.9</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>20</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>58.3</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>21</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>U.S. government-guaranteed corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>48.9</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>17</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>29.8</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>11</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face=serif size=2>U.S.
      government guaranteed collateralized mortgage</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; obligations</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>11.3</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>4</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>17.4</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>6</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Corporate bonds</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>32.1</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>11</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>37.1</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>13</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face=serif size=2>Asset-backed securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>8.8</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>3</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>17.8</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face=serif size=2>7</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face=serif size=2>%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face=serif size=2>Other</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>3.2</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>3.7</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face=serif size=2>1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face=serif size=2>%</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="84%" colSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total marketable
    securities</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%">295.2</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%">100</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%">%</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%">278.0</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%">100</TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%">%</TD></TR></TABLE>
<P align=center><FONT face=serif size=2>26</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition, at March 31, 2009 and December 31, 2008, we had $200.8 million and
$249.5 million, respectively, of cash, cash equivalents, and restricted cash,
primarily held in money market funds that invest in U.S. government
securities.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>During
the first quarter of 2009, as marketable securities in our portfolio matured or
paid down, we purchased primarily U.S. Treasury securities, U.S. government
agency obligations and U.S. government-guaranteed debt. This shift toward higher
quality securities, which we initiated in 2008, continues to reduce the risk
profile, as well as the overall yield, of our portfolio. In particular, we
continue to reduce the proportion of asset-backed securities and corporate bonds
in our portfolio.</FONT><B><FONT face=serif size=2></FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>Capital
Expenditures:</FONT></I></B><B><I><FONT face=serif size=2></FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
additions to property, plant, and equipment totaled $24.7 million and $2.8
million for the first three months of 2009 and 2008, respectively. During the
remainder of 2009, we expect to incur, primarily in connection with expanding
our Rensselaer, New York manufacturing facilities and the new Tarrytown
facilities approximately $80 to $90 million in capital expenditures of which up
to approximately $50 million is reimbursable at our option from our landlord
under the terms of our Tarrytown operating lease.</FONT></P>
<P align=justify><FONT face=serif size=2><STRONG><EM>Amendment to Operating
Lease &#150; Tarrytown, New York Facilities:</EM></STRONG></FONT></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>We currently lease approximately
248,000 square feet of laboratory and office facilities in Tarrytown, New York.
In December 2006, we entered into a new operating lease agreement (as amended in
October 2007 and September 2008) to lease approximately 348,000 square feet of
laboratory and office space at our current Tarrytown location, including
approximately 230,000 square feet in new facilities that are currently under
construction and expected to be completed in mid-2009. The term of the lease
commenced effective June 2008 and will expire in June 2024. In April 2009, we
amended the operating lease agreement to increase the amount of space we will
lease to approximately 389,500 square feet. As amended, the lease contains early
termination options on approximately 159,500 square feet of space. Other terms
and conditions, as previously described in our Annual Report on Form 10-K for
the year ended December 31, 2008, remain unchanged. In connection with the lease
amendment, in April 2009, we terminated a sublease for 16,200 square feet of
space in Tarrytown, New York.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Funding
Requirements:</FONT></I></B> <B><I><FONT face=serif size=2></FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We expect
to continue to incur substantial funding requirements primarily for research and
development activities (including preclinical and clinical testing). Before
taking into account reimbursements from collaborators, we currently anticipate
that approximately 55-65% of our expenditures for 2009 will be directed toward
the preclinical and clinical development of product candidates, including
ARCALYST<SUP>&#174;</SUP></FONT> <FONT face=serif size=2>(rilonacept), aflibercept,
VEGF Trap-Eye, and monoclonal antibodies (including REGN88, REGN421, and
REGN475); approximately 15-20% of our expenditures for 2009 will be applied to
our basic research and early preclinical activities and the remainder of our
expenditures for 2009 will be used for the continued development of our novel
technology platforms, capital expenditures, and general corporate
purposes.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
currently anticipate that in 2009 sales of ARCALYST</FONT><SUP><FONT face=serif size=2></FONT></SUP> <FONT face=serif size=2>for the treatment of CAPS will not
materially enhance or otherwise materially impact our cash flows.</FONT></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In connection with the April 2009
amendment to our operating lease agreement in Tarrytown, New York, as described
above, our funding requirements for operating leases, previously disclosed in
our Annual Report on Form 10-K for the year ended December 31, 2008, will
increase (i) from $9.1 million to $9.4 million for the year ending December 31,
2009, (ii) from $26.8 million to $29.2 million for the two-year period beginning
January 1, 2010, (iii) from $27.2 million to $28.8 million for the two-year
period beginning January 1, 2012, and (iv) from $167.0 million to $182.5 million
for the fiscal years beginning January 1, 2014 and thereafter.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
amount we need to fund operations will depend on various factors, including the
status of competitive products, the success of our research and development
programs, the potential future need to expand our professional and support staff
and facilities, the status of patents and other intellectual property rights,
the delay or failure of a clinical trial of any of our potential drug
candidates, and the continuation, extent, and success of our collaborations with
sanofi-aventis and Bayer HealthCare. Clinical trial costs are dependent, among
other things, on the size and duration of trials, fees charged for services
provided by clinical trial investigators and other third parties, the costs for
manufacturing the product candidate for use in the trials, and for supplies,
laboratory tests, and other expenses. The amount of funding that will be
required for our clinical programs depends upon the results of our research and
preclinical programs and early-stage clinical trials, regulatory requirements,
the duration and results of clinical trials underway and of additional clinical
trials that we decide to initiate, and the various factors that affect the cost
of each trial as described above. Currently, we are required to remit royalties
on product sales of ARCALYST for the treatment of CAPS. In the future, if we are
able to successfully develop, market, and sell ARCALYST for other indications or
certain of our product candidates, we may be required to pay royalties or
otherwise share the profits generated on such sales in connection with our
collaboration and licensing agreements.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We expect
that expenses related to the filing, prosecution, defense, and enforcement of
patent and other intellectual property claims will continue to be substantial as
a result of patent filings and prosecutions in the United States and foreign
countries.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
believe that our existing capital resources, including funding we are entitled
to receive under our collaboration agreements, will enable us to meet operating
needs through at least 2012. However, this is a forward-looking statement based
on our current operating plan, and there may be a change in projected revenues
or expenses that would lead to our capital being consumed significantly before
such time. If there is insufficient capital to fund all of our planned
operations and activities, we believe we would prioritize available capital to
fund selected preclinical and clinical development programs.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>27</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Other
than letters of credit totaling $1.7 million, including a $1.6 million letter of
credit issued to our landlord in connection with our operating lease for
facilities in Tarrytown, New York, as described above, we have no off-balance
sheet arrangements. In addition, we do not guarantee the obligations of any
other entity. As of March 31, 2009, we had no established banking arrangements
through which we could obtain short-term financing or a line of credit. In the
event we need additional financing for the operation of our business, we will
consider collaborative arrangements and additional public or private financing,
including additional equity financing. Factors influencing the availability of
additional financing include our progress in product development, investor
perception of our prospects, and the general condition of the financial markets.
We may not be able to secure the necessary funding through new collaborative
arrangements or additional public or private offerings. If we cannot raise
adequate funds to satisfy our capital requirements, we may have to delay,
scale-back, or eliminate certain of our research and development activities or
future operations. This could materially harm our business.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Future Impact of Recently Issued
Accounting Standards</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In April
2009, the Financial Accounting Standards Board (&#147;FASB&#148;) issued FASB Staff
Position (&#147;FSP&#148;) FAS 107-1 and APB 28-1, <I>Interim Disclosures about Fair Value
of Financial Instruments.</I> This FSP amends SFAS 107, <I>Disclosures about
Fair Value of Financial Instruments,</I> to require entities to provide
disclosures about the fair value of financial instruments in interim financial
information. This FSP also amends APB Opinion No. 28, <I>Interim Financial
Reporting,</I> to require those disclosures in summarized financial information
at interim reporting periods. In addition, an entity shall disclose in the body
or in the accompanying notes of its summarized financial information for interim
reporting periods and in its financial statements for annual reporting periods
the fair value of all financial instruments for which it is practicable to
estimate that value, whether recognized or not recognized in the statement of
financial position, as required by SFAS 107. We are required to adopt FSP 107-1
and APB 28-1 for the quarter ended June 30, 2009. Management does not anticipate
that the adoption of FSP 107-1 and APB 28-1 will have a material impact on our
financial statements.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In April
2009, the FASB issued FSP FAS 115-2 and FAS 124-2, <I>Recognition and
Presentation of Other-Than-Temporary Impairments.</I> This FSP changes existing
guidance for determining whether an impairment to debt securities is other than
temporary; replaces the existing requirement that management assert it has both
the intent and ability to hold an impaired security until recovery with a
requirement that management assert: (<I>a</I>) it does not have the intent to
sell the security; and (<I>b</I>) it is more likely than not it will not have to
sell the security before recovery of its cost basis; requires that an entity
recognize noncredit losses on held-to-maturity debt securities in other
comprehensive income and amortize that amount over the remaining life of the
security in a prospective manner by offsetting the recorded value of the asset
unless the security is subsequently sold or there are additional credit losses;
and requires entities to present the total other-than-temporary impairment in
the statement of earnings with an offset for the amount recognized in other
comprehensive income. When adopting FSP FAS 115-2 and FAS 124-2, entities are
required to record a cumulative-effect adjustment as of the beginning of the
period of adoption to reclassify the noncredit component of a previously
recognized other-temporary impairment from retained earnings to accumulated
other comprehensive income if the entity does not intend to sell the security
and it is not more likely than not that the entity will be required to sell the
security before recovery. We are required to adopt FSP FAS 115-2 and FAS 124-2
for the quarter ended June 30, 2009. Management does not anticipate that the
adoption of FSP FAS 115-2 and FAS 124-2 will have a material impact on our
financial statements.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In April
2009 the FASB issued FSP FAS 157-4, <I>Determining Fair Value When the Volume
and Level of Activity for the Asset or Liability Have Significantly Decreased
and Identifying Transactions That Are Not Orderly.</I> This FSP affirms that the
objective of fair value when the market for an asset is not active is the price
that would be received to sell the asset in an orderly transaction; clarifies
and includes additional factors for determining whether there has been a
significant decrease in market activity for an asset when the market for that
asset is not active; and eliminates the proposed presumption that all
transactions are distressed (not orderly) unless proven otherwise. The FSP
instead requires entities to base its conclusion about whether a transaction was
not orderly on the weight of the evidence. We are required to adopt FSP FAS
157-4 for the quarter ended June 30, 2009. Management does not anticipate that
the adoption of FSP FAS 157-4 will have a material impact on our financial
statements.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>28</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>ITEM 3. QUANTITATIVE AND QUALITATIVE
DISCLOSURE ABOUT MARKET RISK</FONT></B></P>
<P align=justify><I><FONT face=serif size=2>Interest Rate Risk:</FONT></I><FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
earnings and cash flows are subject to fluctuations due to changes in interest
rates primarily from our investment of available cash balances in investment
grade corporate, asset-backed, and U.S. government securities. We do not believe
we are materially exposed to changes in interest rates. Under our current
policies, we do not use interest rate derivative instruments to manage exposure
to interest rate changes. We estimated that a one percent unfavorable change in
interest rates would result in approximately a $1.6 million and $1.8 million
decrease in the fair value of our investment portfolio at March 31, 2009 and
2008, respectively.</FONT></P>
<P align=justify><I><FONT face=serif size=2>Credit Quality Risk:</FONT></I><FONT face=serif size=2></FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
an investment policy that includes guidelines on acceptable investment
securities, minimum credit quality, maturity parameters, and concentration and
diversification. Nonetheless, deterioration of the credit quality of an
investment security subsequent to purchase may subject us to the risk of not
being able to recover the full principal value of the security. In 2007, we
recognized a $5.9 million charge related to marketable securities from two
issuers which we considered to be other than temporarily impaired in value. In
2008, an additional $0.7 million impairment charge was recognized related to one
of these securities and a $1.8 million charge was recognized related to another
marketable security which we considered to be other than temporarily impaired in
value.</FONT><I><FONT face=serif size=2></FONT></I></P>
<P align=justify><B><FONT face=serif size=2>Item 4. Controls and
Procedures</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
management, with the participation of our chief executive officer and chief
financial officer, conducted an evaluation of the effectiveness of our
disclosure controls and procedures (as such term is defined in Rules 13a-15(e)
and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;)), as of the end of the period covered by this report. Based on
this evaluation, our chief executive officer and chief financial officer each
concluded that, as of the end of such period, our disclosure controls and
procedures were effective in ensuring that information required to be disclosed
by us in the reports that we file or submit under the Exchange Act is recorded,
processed, summarized, and reported within the time periods specified in
applicable rules and forms of the Securities and Exchange Commission, and is
accumulated and communicated to our management, including our chief executive
officer and chief financial officer, as appropriate to allow timely decisions
regarding required disclosure.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There has
been no change in our internal control over financial reporting (as such term is
defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the
quarter ended March 31, 2009 that has materially affected, or is reasonably
likely to materially affect, our internal control over financial
reporting.</FONT><B><I><FONT face=serif size=2></FONT></I></B></P>
<P align=justify><B><FONT face=serif size=2>PART II. OTHER
INFORMATION</FONT></B></P>
<P align=justify><B><FONT face=serif size=2>ITEM 1. LEGAL
PROCEEDINGS</FONT></B><B><I><FONT face=serif size=2></FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>From time
to time, we are a party to legal proceedings in the course of our business. We
do not expect any such current legal proceedings to have a material adverse
effect on our business or financial condition.</FONT></P>
<P align=justify><B><FONT face=serif size=2>ITEM 1A. RISK FACTORS</FONT></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
operate in an environment that involves a number of significant risks and
uncertainties. We caution you to read the following risk factors, which have
affected, and/or in the future could affect, our business, operating results,
financial condition, and cash flows. The risks described below include
forward-looking statements, and actual events and our actual results may differ
substantially from those discussed in these forward-looking statements.
Additional risks and uncertainties not currently known to us or that we
currently deem immaterial may also impair our business operations. Furthermore,
additional risks and uncertainties are described under other captions in this
report and should be considered by our investors.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>29</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>Risks Related to Our Financial
Results and Need for Additional Financing</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>We have had a history of
operating losses and we may never achieve profitability. If we continue to incur
operating losses, we may be unable to continue our
operations.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>From
inception on January 8, 1988 through March 31, 2009, we had a cumulative loss of
$893.4 million. If we continue to incur operating losses and fail to become a
profitable company, we may be unable to continue our operations. In the absence
of substantial revenue from the sale of products or other sources, the amount,
timing, nature or source of which cannot be predicted, our losses will continue
as we conduct our research and development activities.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>We may need additional funding in
the future, which may not be available to us, and which may force us to delay,
reduce or eliminate our product development programs or commercialization
efforts.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We will
need to expend substantial resources for research and development, including
costs associated with clinical testing of our product candidates. We believe our
existing capital resources, including funding we are entitled to receive under
our collaboration agreements, will enable us to meet operating needs through at
least 2012; however, one or more of our collaboration agreements may terminate,
our projected revenue may decrease, or our expenses may increase and that would
lead to our capital being consumed significantly before such time. We may
require additional financing in the future and we may not be able to raise such
additional funds. If we are able to obtain additional financing through the sale
of equity or convertible debt securities, such sales may be dilutive to our
shareholders. Debt financing arrangements may require us to pledge certain
assets or enter into covenants that would restrict our business activities or
our ability to incur further indebtedness and may contain other terms that are
not favorable to our shareholders. If we are unable to raise sufficient funds to
complete the development of our product candidates, we may face delay, reduction
or elimination of our research and development programs or preclinical or
clinical trials, in which case our business, financial condition or results of
operations may be materially harmed.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>The value of our investment
portfolio, which includes cash, cash equivalents, and marketable securities, is
influenced by varying economic and market conditions. A decrease in the value of
an asset in our investment portfolio or a default by the issuer may result in
our inability to recover the principal we invested and/or a recognition of a
loss charged against income.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As of
March 31, 2009, cash, cash equivalents, restricted cash, and marketable
securities totaled $496.0 million and represented 73% of our total assets. We
have invested available cash balances primarily in money market funds and U.S.
Treasury, U.S. government agency, corporate, and asset-backed securities. We
consider assets classified as marketable securities to be &#147;available-for-sale,&#148;
as defined by Statement of Financial Accounting Standards No. (SFAS) 115,
<I>Accounting for Certain Investments in Debt and Equity Securities</I>.
Marketable securities totaled $295.2 million at March 31, 2009, are carried at
fair value, and the unrealized gains and losses are included in other
accumulated comprehensive income (loss) as a separate component of stockholders&#146;
equity. If the decline in the value of a security in our investment portfolio is
deemed to be other-than-temporary, we write down the security to its current
fair value and recognize a loss that is charged against income. For example,
during the year ended December 31, 2008, we recorded charges for
other-than-temporary impairments totaling $2.5 million related to two marketable
securities in our investment portfolio. The current economic environment, the
deterioration in the credit quality of some of the issuers of securities that we
hold, and the recent volatility of securities markets increase the risk that we
may not recover the principal we invested and/or there may be further declines
in the market value of securities in our investment portfolio. As a result, we
may incur additional charges against income in future periods for
other-than-temporary impairments or realized losses upon a security&#146;s sale or
maturity, and such amounts may be material.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to
ARCALYST<SUP>&#174;</SUP> (rilonacept) and the Development of Our Product
Candidates</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>Successful development of any of
our product candidates is highly uncertain.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Only a
small minority of all research and development programs ultimately result in
commercially successful drugs. Even if clinical trials demonstrate safety and
effectiveness of any of our product candidates for a specific disease and the
necessary regulatory approvals are obtained, the commercial success of any of
our product candidates will depend upon their acceptance by patients, the
medical community, and third-party payers and on our partners&#146; ability to
successfully manufacture and commercialize our product candidates. Our product
candidates are delivered either by intravenous infusion or by intravitreal or
subcutaneous injections, which are generally less well received by patients than
tablet or capsule delivery. If our products are not successfully commercialized,
we will not be able to recover the significant investment we have made in
developing such products and our business would be severely harmed.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>30</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
studying aflibercept, VEGF Trap-Eye, ARCALYST<SUP>&#174;</SUP> (rilonacept), and our
antibody candidates in a wide variety of indications. Many of these current
trials are exploratory studies designed to identify what diseases and uses, if
any, are best suited for our product candidates. It is likely that our product
candidates will not demonstrate the requisite efficacy and/or safety profile to
support continued development for most of the indications that are being, or are
planned to be, studied. In fact, our product candidates may not demonstrate the
requisite efficacy and safety profile to support the continued development for
any of the indications or uses.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Clinical trials required for our
product candidates are expensive and time-consuming, and their outcome is highly
uncertain. If any of our drug trials are delayed or yield unfavorable results,
we will have to delay or may be unable to obtain regulatory approval for our
product candidates.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We must
conduct extensive testing of our product candidates before we can obtain
regulatory approval to market and sell them. We need to conduct both preclinical
animal testing and human clinical trials. Conducting these trials is a lengthy,
time-consuming, and expensive process. These tests and trials may not achieve
favorable results for many reasons, including, among others, failure of the
product candidate to demonstrate safety or efficacy, the development of serious
or life-threatening adverse events (or side effects) caused by or connected with
exposure to the product candidate, difficulty in enrolling and maintaining
subjects in the clinical trial, lack of sufficient supplies of the product
candidate or comparator drug, and the failure of clinical investigators, trial
monitors and other consultants, or trial subjects to comply with the trial plan
or protocol. A clinical trial may fail because it did not include a sufficient
number of patients to detect the endpoint being measured or reach statistical
significance. A clinical trial may also fail because the dose(s) of the
investigational drug included in the trial were either too low or too high to
determine the optimal effect of the investigational drug in the disease
setting.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We will
need to reevaluate any drug candidate that does not test favorably and either
conduct new trials, which are expensive and time consuming, or abandon the drug
development program. Even if we obtain positive results from preclinical or
clinical trials, we may not achieve the same success in future trials. Many
companies in the biopharmaceutical industry, including us, have suffered
significant setbacks in clinical trials, even after promising results have been
obtained in earlier trials. The failure of clinical trials to demonstrate safety
and effectiveness for the desired indication(s) could harm the development of
our product candidate(s), and our business, financial condition, and results of
operations may be materially harmed.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Serious complications or side
effects have occurred, and may continue to occur, in connection with the use of
our approved product and in clinical trials of some of our product candidates
which could cause our regulatory approval to be revoked or otherwise negatively
affected or lead to delay or discontinuation of development of our product
candidates which could severely harm our business.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>During
the conduct of clinical trials, patients report changes in their health,
including illnesses, injuries, and discomforts, to their study doctor. Often, it
is not possible to determine whether or not the drug candidate being studied
caused these conditions. Various illnesses, injuries, and discomforts have been
reported from time-to-time during clinical trials of our product candidates. It
is possible as we test our drug candidates in larger, longer, and more extensive
clinical programs, illnesses, injuries, and discomforts that were observed in
earlier trials, as well as conditions that did not occur or went undetected in
smaller previous trials, will be reported by patients. Many times, side effects
are only detectable after investigational drugs are tested in large scale, Phase
3 clinical trials or, in some cases, after they are made available to patients
after approval. If additional clinical experience indicates that any of our
product candidates has many side effects or causes serious or life-threatening
side effects, the development of the product candidate may fail or be delayed,
which would severely harm our business.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>31</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
aflibercept (VEGF Trap) is being studied for the potential treatment of certain
types of cancer and our VEGF Trap-Eye candidate is being studied in diseases of
the eye. There are many potential safety concerns associated with significant
blockade of vascular endothelial growth factor, or VEGF, that may limit our
ability to successfully develop aflibercept and VEGF Trap-Eye. These serious and
potentially life-threatening risks, based on clinical and preclinical experience
of VEGF inhibitors, include bleeding, intestinal perforation, hypertension,
proteinuria, heart attack, and stroke. In addition, patients given infusions of
any protein, including VEGF Trap delivered through intravenous administration,
may develop severe hypersensitivity reactions or infusion reactions. Other VEGF
blockers have reported side effects that became evident only after large scale
trials or after marketing approval and large number of patients were treated.
These and other complications or side effects could harm the development of
aflibercept for the treatment of cancer or VEGF Trap-Eye for the treatment of
diseases of the eye.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
tested ARCALYST in only a small number of patients with CAPS. As more patients
begin to use our product and as we test it in new disease settings, new risks
and side effects associated with ARCALYST may be discovered, and risks
previously viewed as inconsequential could be determined to be significant. Like
cytokine antagonists such as Kineret<SUP>&#174;</SUP> (Amgen, Inc.),
Enbrel<SUP>&#174;</SUP> (Immunex Corporation), and Remicade<SUP>&#174;</SUP> (Centocor,
Inc.), ARCALYST affects the immune defense system of the body by blocking some
of its functions. Therefore, ARCALYST may interfere with the body&#146;s ability to
fight infections. Treatment with Kineret (Amgen), a medication that works
through the inhibition of IL-1, has been associated with an increased risk of
serious infections, and serious, life threatening infections have been reported
in patients taking ARCALYST. These or other complications or side effects could
cause regulatory authorities to revoke approvals of ARCALYST. Alternatively, we
may be required to conduct additional clinical trials, make changes in the
labeling of our product, or limit or abandon our efforts to develop ARCALYST in
new disease settings. These side effects may also result in a reduction, or even
the elimination, of sales of ARCALYST in approved indications.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>ARCALYST<SUP>&#174;</SUP> (rilonacept)
and our product candidates in development are recombinant proteins that could
cause an immune response, resulting in the creation of harmful or neutralizing
antibodies against the therapeutic protein.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to the safety, efficacy, manufacturing, and regulatory hurdles faced by
our product candidates, the administration of recombinant proteins frequently
causes an immune response, resulting in the creation of antibodies against the
therapeutic protein. The antibodies can have no effect or can totally neutralize
the effectiveness of the protein, or require that higher doses be used to obtain
a therapeutic effect. In some cases, the antibody can cross react with the
patient&#146;s own proteins, resulting in an &#147;auto-immune&#148; type disease. Whether
antibodies will be created can often not be predicted from preclinical or
clinical experiments, and their detection or appearance is often delayed, so
that there can be no assurance that neutralizing antibodies will not be detected
at a later date, in some cases even after pivotal clinical trials have been
completed. Antibodies directed against the receptor domains of rilonacept were
detected in patients with CAPS after treatment with ARCALYST. Nineteen of 55
subjects (35%) who received ARCALYST for at least 6 weeks tested positive for
treatment-emerging binding antibodies on at least one occasion. To date, no side
effects related to antibodies were observed in these subjects and there were no
observed effects on drug efficacy or drug levels. It is possible that as we
continue to test aflibercept and VEGF Trap-Eye with more sensitive assays in
different patient populations and larger clinical trials, we will find that
subjects given aflibercept and VEGF Trap-Eye develop antibodies to these product
candidates, and may also experience side effects related to the antibodies,
which could adversely impact the development of such candidates.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>We may be unable to formulate or
manufacture our product candidates in a way that is suitable for clinical or
commercial use.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Changes
in product formulations and manufacturing processes may be required as product
candidates progress in clinical development and are ultimately commercialized.
If we are unable to develop suitable product formulations or manufacturing
processes to support large scale clinical testing of our product candidates,
including aflibercept, VEGF Trap-Eye, and our antibody candidates, we may be
unable to supply necessary materials for our clinical trials, which would delay
the development of our product candidates. Similarly, if we are unable to supply
sufficient quantities of our product or develop product formulations suitable
for commercial use, we will not be able to successfully commercialize our
product candidates.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>32</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><FONT face=serif size=2>Risks Related to Intellectual
Property</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If we cannot protect the
confidentiality of our trade secrets or our patents are insufficient to protect
our proprietary rights, our business and competitive position will be
harmed.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
business requires using sensitive and proprietary technology and other
information that we protect as trade secrets. We seek to prevent improper
disclosure of these trade secrets through confidentiality agreements. If our
trade secrets are improperly exposed, either by our own employees or our
collaborators, it would help our competitors and adversely affect our business.
We will be able to protect our proprietary rights from unauthorized use by third
parties only to the extent that our rights are covered by valid and enforceable
patents or are effectively maintained as trade secrets. The patent position of
biotechnology companies involves complex legal and factual questions and,
therefore, enforceability cannot be predicted with certainty. Our patents may be
challenged, invalidated, or circumvented. Patent applications filed outside the
United States may be challenged by third parties who file an opposition. Such
opposition proceedings are increasingly common in the European Union and are
costly to defend. We have patent applications that are being opposed and it is
likely that we will need to defend additional patent applications in the future.
Our patent rights may not provide us with a proprietary position or competitive
advantages against competitors. Furthermore, even if the outcome is favorable to
us, the enforcement of our intellectual property rights can be extremely
expensive and time consuming.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>We may be restricted in our
development and/or commercialization activities by, and could be subject to
damage awards if we are found to have infringed, third party patents or other
proprietary rights.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
commercial success depends significantly on our ability to operate without
infringing the patents and other proprietary rights of third parties. Other
parties may allege that they have blocking patents to our products in clinical
development, either because they claim to hold proprietary rights to the
composition of a product or the way it is manufactured or used. Moreover, other
parties may allege that they have blocking patents to antibody products made
using our</FONT> <FONT face=serif size=2><I>VelocImmune</I><SUP>&#174;</SUP>
technology, either because of the way the antibodies are discovered or produced
or because of a proprietary position covering an antibody or the antibody&#146;s
target.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
aware of patents and pending applications owned by Genentech/Roche that claim
certain chimeric VEGF receptor compositions. Although we do not believe that
aflibercept or VEGF Trap-Eye infringes any valid claim in these patents or
patent applications, Genentech/Roche could initiate a lawsuit for patent
infringement and assert that its patents are valid and cover aflibercept or VEGF
Trap-Eye. Genentech/Roche may be motivated to initiate such a lawsuit at some
point in an effort to impair our ability to develop and sell aflibercept or VEGF
Trap-Eye, which represent potential competitive threats to Genentech/Roche&#146;s
VEGF-binding products and product candidates. An adverse determination by a
court in any such potential patent litigation would likely materially harm our
business by requiring us to seek a license, which may not be available, or
resulting in our inability to manufacture, develop and sell aflibercept or VEGF
Trap-Eye or in a damage award.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
aware of patents and pending applications owned by Roche that claim antibodies
to the interleukin-6 receptor and methods of treating rheumatoid arthritis with
such antibodies. We are developing REGN88, an antibody to the interleukin-6
receptor, for the treatment of rheumatoid arthritis. Although we do not believe
that REGN88 infringes any valid claim in these patents or patent applications,
Roche could initiate a lawsuit for patent infringement and assert its patents
are valid and cover REGN88.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
aware of a U.S. patent jointly owned by Genentech/Roche and City of Hope
relating to the production of recombinant antibodies in host cells. We currently
produce our antibody product candidates using recombinant antibodies from host
cells and may choose to produce additional antibody product candidates in this
manner. Neither ARCALYST<SUP>&#174;</SUP> (rilonacept), aflibercept, nor VEGF
Trap-Eye are recombinant antibodies. If any of our antibody product candidates
are produced in a manner subject to valid claims in the Genentech/Roche patent,
then we may need to obtain a license from Genentech/Roche, should one be
available. Genentech/Roche has licensed this patent to several different
companies under confidential license agreements. If we desire a license for any
of our antibody product candidates and are unable to obtain a license on
commercially reasonable terms or at all, we may be restricted in our ability to
use Genentech/Roche&#146;s techniques to make recombinant antibodies in or to import
them into the United States.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Further,
we are aware of a number of other third party patent applications that, if
granted, with claims as currently drafted, may cover our current or planned
activities. We cannot assure you that our products and/or actions in
manufacturing and selling our product candidates will not infringe such
patents.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>33</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Any
patent holders could sue us for damages and seek to prevent us from
manufacturing, selling, or developing our drug candidates, and a court may find
that we are infringing validly issued patents of third parties. In the event
that the manufacture, use, or sale of any of our clinical candidates infringes
on the patents or violates other proprietary rights of third parties, we may be
prevented from pursuing product development, manufacturing, and
commercialization of our drugs and may be required to pay costly damages. Such a
result may materially harm our business, financial condition, and results of
operations. Legal disputes are likely to be costly and time consuming to
defend.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We seek
to obtain licenses to patents when, in our judgment, such licenses are needed.
If any licenses are required, we may not be able to obtain such licenses on
commercially reasonable terms, if at all. The failure to obtain any such license
could prevent us from developing or commercializing any one or more of our
product candidates, which could severely harm our business.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Regulatory and Litigation
Risks</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If we do not obtain regulatory
approval for our product candidates, we will not be able to market or sell
them.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We cannot
sell or market products without regulatory approval. Although we obtained
regulatory approval for ARCALYST<SUP>&#174;</SUP> (rilonacept) for the treatment of
CAPS in the United States, we may be unable to obtain regulatory approval of
ARCALYST in any other country or in any other indication. Regulatory agencies
outside the United States may require additional information or data with
respect to any future submission for ARCALYST for the treatment of
CAPS.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>If we do
not obtain and maintain regulatory approval for our product candidates,
including ARCALYST for the treatment of diseases other than CAPS, the value of
our company and our results of operations will be harmed. In the United States,
we must obtain and maintain approval from the United States Food and Drug
Administration (FDA) for each drug we intend to sell. Obtaining FDA approval is
typically a lengthy and expensive process, and approval is highly uncertain.
Foreign governments also regulate drugs distributed in their country and
approval in any country is likely to be a lengthy and expensive process, and
approval is highly uncertain. Except for the FDA approval of ARCALYST for the
treatment of CAPS, none of our product candidates has ever received regulatory
approval to be marketed and sold in the United States or any other country. We
may never receive regulatory approval for any of our product
candidates.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Before
approving a new drug or biologic product, the FDA requires that the facilities
at which the product will be manufactured be in compliance with current good
manufacturing practices, or cGMP requirements. Manufacturing product candidates
in compliance with these regulatory requirements is complex, time-consuming, and
expensive. To be successful, our products must be manufactured for development,
following approval, in commercial quantities, in compliance with regulatory
requirements, and at competitive costs. If we or any of our product
collaborators or third-party manufacturers, product packagers, or labelers are
unable to maintain regulatory compliance, the FDA can impose regulatory
sanctions, including, among other things, refusal to approve a pending
application for a new drug or biologic product, or revocation of a pre-existing
approval. As a result, our business, financial condition, and results of
operations may be materially harmed.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to the FDA and other regulatory agency regulations in the United
States, we are subject to a variety of foreign regulatory requirements governing
human clinical trials, manufacturing, marketing and approval of drugs, and
commercial sale and distribution of drugs in foreign countries. The foreign
regulatory approval process includes all of the risks associated with FDA
approval as well as country specific regulations. Whether or not we obtain FDA
approval for a product in the United States, we must obtain approval by the
comparable regulatory authorities of foreign countries before we can commence
clinical trials or marketing of ARCALYST for the treatment of CAPS or any of our
product candidates in those countries.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>If the testing or use of our
products harms people, we could be subject to costly and damaging product
liability claims.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
testing, manufacturing, marketing, and sale of drugs for use in people expose us
to product liability risk. Any informed consent or waivers obtained from people
who sign up for our clinical trials may not protect us from liability or the
cost of litigation. We may be subject to claims by CAPS patients who use
ARCALYST that they have been injured by a side effect associated with the drug.
Our product liability insurance may not cover all potential liabilities or may
not completely cover any liability arising from any such litigation. Moreover,
we may not have access to liability insurance or be able to maintain our
insurance on acceptable terms.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>34</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>If we market and sell
ARCALYST</FONT></I></B><B><SUP><FONT face=serif size=2>&#174;</FONT></SUP></B>
<B><I><FONT face=serif size=2>(rilonacept) in a way that violates federal or
state fraud and abuse laws, we may be subject to civil or criminal
penalties.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to FDA and related regulatory requirements, we are subject to health
care &#147;fraud and abuse&#148; laws, such as the federal False Claims Act, the
anti-kickback provisions of the federal Social Security Act, and other state and
federal laws and regulations. Federal and state anti-kickback laws prohibit,
among other things, knowingly and willfully offering, paying, soliciting or
receiving remuneration to induce, or in return for, purchasing, leasing,
ordering or arranging for the purchase, lease or order of any health care item
or service reimbursable under Medicare, Medicaid, or other federally or state
financed health care programs.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Federal
false claims laws prohibit any person from knowingly presenting, or causing to
be presented, a false claim for payment to the federal government, or knowingly
making, or causing to be made, a false statement to get a false claim paid.
Pharmaceutical companies have been prosecuted under these laws for a variety of
alleged promotional and marketing activities, such as allegedly providing free
product to customers with the expectation that the customers would bill federal
programs for the product; reporting to pricing services inflated average
wholesale prices that were then used by federal programs to set reimbursement
rates; engaging in promotion for uses that the FDA has not approved, or
off-label uses, that caused claims to be submitted to Medicaid for non-covered
off-label uses; and submitting inflated best price information to the Medicaid
Rebate program.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
majority of states also have statutes or regulations similar to the federal
anti-kickback law and false claims laws, which apply to items and services
reimbursed under Medicaid and other state programs, or, in several states, apply
regardless of the payer. Sanctions under these federal and state laws may
include civil monetary penalties, exclusion of a manufacturer&#146;s products from
reimbursement under government programs, criminal fines, and
imprisonment.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Even if
we are not determined to have violated these laws, government investigations
into these issues typically require the expenditure of significant resources and
generate negative publicity, which would also harm our financial condition.
Because of the breadth of these laws and the narrowness of the safe harbors, it
is possible that some of our business activities could be subject to challenge
under one or more of such laws.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In recent
years, several states and localities, including California, the District of
Columbia, Massachusetts, Maine, Minnesota, Nevada, New Mexico, Vermont, and West
Virginia, have enacted legislation requiring pharmaceutical companies to
establish marketing compliance programs, and file periodic reports with the
state or make periodic public disclosures on sales, marketing, pricing, clinical
trials, and other activities. Similar legislation is being considered in other
states. Many of these requirements are new and uncertain, and the penalties for
failure to comply with these requirements are unclear. Nonetheless, if we are
found not to be in full compliance with these laws, we could face enforcement
action and fines and other penalties, and could receive adverse
publicity.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Our operations may involve
hazardous materials and are subject to environmental, health, and safety laws
and regulations. We may incur substantial liability arising from our activities
involving the use of hazardous materials.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As a
biopharmaceutical company with significant manufacturing operations, we are
subject to extensive environmental, health, and safety laws and regulations,
including those governing the use of hazardous materials. Our research and
development and manufacturing activities involve the controlled use of
chemicals, viruses, radioactive compounds, and other hazardous materials. The
cost of compliance with environmental, health, and safety regulations is
substantial. If an accident involving these materials or an environmental
discharge were to occur, we could be held liable for any resulting damages, or
face regulatory actions, which could exceed our resources or insurance
coverage.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>35</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>Changes in the securities laws
and regulations have increased, and are likely to continue to increase, our
costs.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
Sarbanes-Oxley Act of 2002, which became law in July 2002, has required changes
in some of our corporate governance, securities disclosure and compliance
practices. In response to the requirements of that Act, the SEC and the NASDAQ
Stock Market have promulgated rules and listing standards covering a variety of
subjects. Compliance with these rules and listing standards has increased our
legal costs, and significantly increased our accounting and auditing costs, and
we expect these costs to continue. These developments may make it more difficult
and more expensive for us to obtain directors&#146; and officers&#146; liability
insurance. Likewise, these developments may make it more difficult for us to
attract and retain qualified members of our board of directors, particularly
independent directors, or qualified executive officers.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>In future years, if we are unable
to conclude that our internal control over financial reporting is effective, the
market value of our Common Stock could be adversely affected.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>As
directed by Section 404 of the Sarbanes-Oxley Act of 2002, the SEC adopted rules
requiring public companies to include a report of management on the Company&#146;s
internal control over financial reporting in their annual reports on Form 10-K
that contains an assessment by management of the effectiveness of our internal
control over financial reporting. In addition, the independent registered public
accounting firm auditing our financial statements must attest to and report on
the effectiveness of our internal control over financial reporting. Our
independent registered public accounting firm provided us with an unqualified
report as to the effectiveness of our internal control over financial reporting
as of December 31, 2008, which report is included in our Annual Report on Form
10-K for the fiscal year ended December 31, 2008. However, we cannot assure you
that management or our independent registered public accounting firm will be
able to provide such an unqualified report as of future year-ends. In this
event, investors could lose confidence in the reliability of our financial
statements, which could result in a decrease in the market value of our Common
Stock. In addition, if it is determined that deficiencies in the design or
operation of internal controls exist and that they are reasonably likely to
adversely affect our ability to record, process, summarize, and report financial
information, we would likely incur additional costs to remediate these
deficiencies and the costs of such remediation could be material.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Changes in laws and regulations
affecting the healthcare industry could adversely affect our
business.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>All
aspects of our business, including research and development, manufacturing,
marketing, pricing, sales, litigation, and intellectual property rights, are
subject to extensive legislation and regulation. Changes in applicable federal
and state laws and agency regulations could have a material adverse effect on
our business. These include:</FONT></P>
<UL style="TEXT-ALIGN: justify">
  <LI><FONT size=2>changes in the FDA and foreign regulatory processes for new
  therapeutics that may delay or prevent the approval of any of our current or
  future product candidates;</FONT>
  <LI><FONT size=2>new laws, regulations, or judicial decisions related to
  healthcare availability or the payment for healthcare products and services,
  including prescription drugs, that would make it more difficult for us to
  market and sell products once they are approved by the FDA or foreign
  regulatory agencies; and</FONT>
  <LI><FONT size=2>changes in FDA and foreign regulations that may require
  additional safety monitoring prior to or after the introduction of new
  products to market, which could materially increase our costs of doing
  business.</FONT></LI></UL>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
enactment in the United States of the Medicare Prescription Drug Improvement and
Modernization Act of 2003 and possible legislation which could ease the entry of
competing follow-on biologics into the marketplace are examples of changes and
possible changes in laws that could adversely affect our business.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to Our Reliance on
Third Parties</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If our antibody collaboration
with sanofi-aventis is terminated, our business operations and our ability to
discover, develop, manufacture, and commercialize our pipeline of product
candidates in the time expected, or at all, would be materially
harmed.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
heavily on the funding from sanofi-aventis to support our target discovery and
antibody research and development programs. Sanofi-aventis has committed to pay
up to $400 million between 2009 and 2012 to fund our efforts to identify and
validate drug discovery targets and pre-clinically develop fully human
monoclonal antibodies against such targets. In addition, sanofi-aventis funds
almost all of the development expenses incurred by both companies in connection
with the clinical development of antibodies that sanofi-aventis elects to
co-develop with us. We rely on sanofi-aventis to fund these activities. In
addition, with respect to those antibodies that sanofi-aventis elects to
co-develop with us, such as REGN88, REGN421, and REGN475, we rely on
sanofi-aventis to lead much of the clinical development efforts and assist with
obtaining regulatory approval, particularly outside the United States. We also
rely on sanofi-aventis to lead the commercialization efforts to support all of
the antibody products that are co-developed by sanofi-aventis and us. If
sanofi-aventis does not elect to co-develop the antibodies that we discover or
opts-out of their development, we would be required to fund and oversee on our
own the clinical trials, any regulatory responsibilities, and the ensuing
commercialization efforts to support our antibody products. If sanofi-aventis
terminates the antibody collaboration or fails to comply with its payment
obligations thereunder, our business, financial condition, and results of
operations would be materially harmed. We would be required to either expend
substantially more resources than we have anticipated to support our research
and development efforts, which could require us to seek additional funding that
might not be available on favorable terms or at all, or materially cut back on
such activities. While we cannot assure you that any of the antibodies from this
collaboration will ever be successfully developed and commercialized, if
sanofi-aventis does not perform its obligations with respect to antibodies that
it elects to co-develop, our ability to develop, manufacture, and commercialize
these antibody product candidates will be significantly adversely
affected.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>36</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>If our collaboration with
sanofi-aventis for aflibercept (VEGF Trap) is terminated, or sanofi-aventis
materially breaches its obligations thereunder, our business operations and
financial condition, and our ability to develop, manufacture, and commercialize
aflibercept in the time expected, or at all, would be materially
harmed.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
heavily on sanofi-aventis to lead much of the development of aflibercept.
Sanofi-aventis funds all of the development expenses incurred by both companies
in connection with the aflibercept program. If the aflibercept program
continues, we will rely on sanofi-aventis to assist with funding the aflibercept
program, provide commercial manufacturing capacity, enroll and monitor clinical
trials, obtain regulatory approval, particularly outside the United States, and
lead the commercialization of aflibercept. While we cannot assure you that
aflibercept will ever be successfully developed and commercialized, if
sanofi-aventis does not perform its obligations in a timely manner, or at all,
our ability to develop, manufacture, and commercialize aflibercept in cancer
indications will be significantly adversely affected. Sanofi-aventis has the
right to terminate its collaboration agreement with us at any time upon twelve
months advance notice. If sanofi-aventis were to terminate its collaboration
agreement with us, we would not have the resources or skills to replace those of
our partner, which could require us to seek additional funding that might not be
available on favorable terms or at all, and could cause significant delays in
the development and/or manufacture of aflibercept and result in substantial
additional costs to us. We have limited commercial capabilities and would have
to develop or outsource these capabilities. Termination of the sanofi-aventis
collaboration agreement for aflibercept would create substantial new and
additional risks to the successful development and commercialization of
aflibercept.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>If our collaboration with Bayer
HealthCare for VEGF Trap-Eye is terminated, or Bayer HealthCare materially
breaches its obligations thereunder, our business, operations and financial
condition, and our ability to develop and commercialize VEGF Trap-Eye in the
time expected, or at all, would be materially harmed.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
heavily on Bayer HealthCare to assist with the development of VEGF Trap-Eye.
Under our agreement with them, Bayer HealthCare is required to fund
approximately half of the development expenses incurred by both companies in
connection with the global VEGF Trap-Eye development program. If the VEGF
Trap-Eye program continues, we will rely on Bayer HealthCare to assist with
funding the VEGF Trap-Eye development program, lead the development of VEGF
Trap-Eye outside the United States, obtain regulatory approval outside the
United States, and provide all sales, marketing and commercial support for the
product outside the United States. In particular, Bayer HealthCare has
responsibility for selling VEGF Trap-Eye outside the United States using its
sales force. While we cannot assure you that VEGF Trap-Eye will ever be
successfully developed and commercialized, if Bayer HealthCare does not perform
its obligations in a timely manner, or at all, our ability to develop,
manufacture, and commercialize VEGF Trap-Eye outside the United States will be
significantly adversely affected. Bayer HealthCare has the right to terminate
its collaboration agreement with us at any time upon six or twelve months
advance notice, depending on the circumstances giving rise to termination. If
Bayer HealthCare were to terminate its collaboration agreement with us, we would
not have the resources or skills to replace those of our partner, which could
require us to seek additional funding that might not be available on favorable
terms or at all, and could cause significant delays in the development and/or
commercialization of VEGF Trap-Eye outside the United States and result in
substantial additional costs to us. We have limited commercial capabilities and
would have to develop or outsource these capabilities outside the United States.
Termination of the Bayer HealthCare collaboration agreement would create
substantial new and additional risks to the successful development and
commercialization of VEGF Trap-Eye.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>37</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>Our collaborators and service
providers may fail to perform adequately in their efforts to support the
development, manufacture, and commercialization of
ARCALYST</FONT></I></B><B><FONT face=serif size=2><SUP>&#174;</SUP></FONT></B>
<B><I><FONT face=serif size=2>(rilonacept) and our drug
candidates.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We depend
upon third-party collaborators, including sanofi-aventis, Bayer HealthCare, and
service providers such as clinical research organizations, outside testing
laboratories, clinical investigator sites, and third-party manufacturers and
product packagers and labelers, to assist us in the manufacture and development
of our product candidates. If any of our existing collaborators or service
providers breaches or terminates its agreement with us or does not perform its
development or manufacturing services under an agreement in a timely manner or
at all, we could experience additional costs, delays, and difficulties in the
manufacture, development, or ultimate commercialization of our product
candidates.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We rely
on third party service providers to support the distribution of ARCALYST and
many other related activities in connection with the commercialization of
ARCALYST for the treatment of CAPS. We cannot be certain that these third
parties will perform adequately. If these service providers do not perform their
services adequately, our efforts to market and sell ARCALYST for the treatment
of CAPS will not be successful.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to the Manufacture of
Our Product Candidates</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>We have limited manufacturing
capacity, which could inhibit our ability to successfully develop or
commercialize our drugs.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
manufacturing facility is likely to be inadequate to produce sufficient
quantities of product for commercial sale. We intend to rely on our corporate
collaborators, as well as contract manufacturers, to produce the large
quantities of drug material needed for commercialization of our products. We
rely entirely on third-party manufacturers for filling and finishing services.
We will have to depend on these manufacturers to deliver material on a timely
basis and to comply with regulatory requirements. If we are unable to supply
sufficient material on acceptable terms, or if we should encounter delays or
difficulties in our relationships with our corporate collaborators or contract
manufacturers, our business, financial condition, and results of operations may
be materially harmed.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We must
expand our own manufacturing capacity to support the planned growth of our
clinical pipeline. Moreover, we may expand our manufacturing capacity to support
commercial production of active pharmaceutical ingredients, or API, for our
product candidates. This will require substantial additional expenditures, and
we will need to hire and train significant numbers of employees and managerial
personnel to staff our facility. Start-up costs can be large and scale-up
entails significant risks related to process development and manufacturing
yields. We may be unable to develop manufacturing facilities that are sufficient
to produce drug material for clinical trials or commercial use. This may delay
our clinical development plans and interfere with our efforts to commercialize
our products. In addition, we may be unable to secure adequate filling and
finishing services to support our products. As a result, our business, financial
condition, and results of operations may be materially harmed.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We may be
unable to obtain key raw materials and supplies for the manufacture of ARCALYST
and our product candidates. In addition, we may face difficulties in developing
or acquiring production technology and managerial personnel to manufacture
sufficient quantities of our product candidates at reasonable costs and in
compliance with applicable quality assurance and environmental regulations and
governmental permitting requirements.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>If any of our clinical programs
are discontinued, we may face costs related to the unused capacity at our
manufacturing facilities.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
large-scale manufacturing operations in Rensselaer, New York. We use our
facilities to produce bulk product for clinical and preclinical candidates for
ourselves and our collaborations. If our clinical candidates are discontinued,
we will have to absorb one hundred percent of related overhead costs and
inefficiencies.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>38</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><STRONG><EM><FONT size=2>Third-party supply failures or a
business interruption at our manufacturing facility in Rensselaer, New York
could adversely affect our ability to supply our
products.</FONT></EM></STRONG></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We
manufacture all of our bulk drug materials for ARCALYST and our product
candidates at our manufacturing facility in Rensselaer, New York. We would be
unable to supply our product requirements if we were to cease production due to
regulatory requirements or action, business interruptions, labor shortages or
disputes, contaminations, or other problems at the facility.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Certain
raw materials necessary for manufacturing and formulation of ARCALYST and our
product candidates are provided by single-source unaffiliated third-party
suppliers. In addition, we rely on certain third parties to perform filling,
finishing, distribution, and other services related to the manufacture of our
products. We would be unable to obtain these raw materials or services for an
indeterminate period of time if any of these third-parties were to cease or
interrupt production or otherwise fail to supply these materials, products, or
services to us for any reason, including due to regulatory requirements or
action, adverse financial developments at or affecting the supplier, business
interruptions, or labor shortages or disputes. This, in turn, could materially
and adversely affect our ability to manufacture or supply ARCALYST or our
product candidates for use in clinical trials, which could materially and
adversely affect our business and future prospects.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Also,
certain of the raw materials required in the manufacturing and the formulation
of our clinical candidates may be derived from biological sources, including
mammalian tissues, bovine serum, and human serum albumin. There are certain
European regulatory restrictions on using these biological source materials. If
we are required to substitute for these sources to comply with European
regulatory requirements, our clinical development activities may be delayed or
interrupted.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to Commercialization
of Products</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>If we are unable to establish
sales, marketing, and distribution capabilities, or enter into agreements with
third parties to do so, we will be unable to successfully market and sell future
products.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
marketing and selling ARCALYST for the treatment of CAPS ourselves in the United
States, primarily through third party service providers. We have no sales or
distribution personnel in the United States and have only a small staff with
commercial capabilities. We have no sales, marketing, commercial, or
distribution capabilities outside the United States. If we are unable to obtain
those capabilities, either by developing our own organizations or entering into
agreements with service providers, even if our current or future product
candidates receive marketing approval, we will not be able to successfully sell
those products. In that event, we will not be able to generate significant
revenue, even if our product candidates are approved. We cannot guarantee that
we will be able to hire the qualified sales and marketing personnel we need or
that we will be able to enter into marketing or distribution agreements with
third-party providers on acceptable terms, if at all. Under the terms of our
collaboration agreement with sanofi-aventis, we currently rely on sanofi-aventis
for sales, marketing, and distribution of aflibercept in cancer indications,
should it be approved in the future by regulatory authorities for marketing. We
will have to rely on a third party or devote significant resources to develop
our own sales, marketing, and distribution capabilities for our other product
candidates, including VEGF Trap-Eye in the United States, and we may be
unsuccessful in developing our own sales, marketing, and distribution
organization.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>There may be too few patients
with CAPS to profitably commercialize ARCALYST</FONT></I></B><B><FONT face=serif size=2><SUP>&#174;</SUP></FONT></B> <B><I><FONT face=serif size=2>(rilonacept) in
this indication.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our only
approved product is ARCALYST for the treatment of CAPS, a group of rare,
inherited auto-inflammatory diseases. These rare diseases affect a very small
group of people. The incidence of CAPS has been reported to be approximately 1
in 1,000,000 people in the United States. Although the incidence rate of CAPS in
Europe has not been reported, it is known to be a rare set of diseases. As a
result, there may be too few patients with CAPS to profitably commercialize
ARCALYST in this indication.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Even if our product candidates
are approved for marketing, their commercial success is highly uncertain because
our competitors have received approval for products with a similar mechanism of
action, and competitors may get to the marketplace with better or lower cost
drugs.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There is
substantial competition in the biotechnology and pharmaceutical industries from
pharmaceutical, biotechnology, and chemical companies. Many of our competitors
have substantially greater research, preclinical and clinical product
development and manufacturing capabilities, and financial, marketing, and human
resources than we do. Our smaller competitors may also enhance their competitive
position if they acquire or discover patentable inventions, form collaborative
arrangements, or merge with large pharmaceutical companies. Even if we achieve
product commercialization, our competitors have achieved, and may continue to
achieve, product commercialization before our products are approved for
marketing and sale.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>39</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Genentech/Roche has an approved VEGF antagonist, Avastin<SUP>&#174;</SUP>
(bevacizumab), on the market for treating certain cancers and many different
pharmaceutical and biotechnology companies are working to develop competing VEGF
antagonists, including Novartis, Amgen, Imclone/Eli Lilly, Pfizer, AstraZeneca,
and GlaxoSmithKline plc. Many of these molecules are farther along in
development than aflibercept and may offer competitive advantages over our
molecule. Each of Pfizer and Onyx Pharmaceuticals, (together with its partner
Bayer HealthCare) has received approval from the FDA to market and sell an oral
medication that targets tumor cell growth and new vasculature formation that
fuels the growth of tumors. The marketing approvals for Genentech/Roche&#146;s VEGF
antagonist, Avastin, and their extensive, ongoing clinical development plan for
Avastin in other cancer indications, make it more difficult for us to enroll
patients in clinical trials to support aflibercept and to obtain regulatory
approval of aflibercept in these cancer settings. This may delay or impair our
ability to successfully develop and commercialize aflibercept. In addition, even
if aflibercept is ever approved for sale for the treatment of certain cancers,
it will be difficult for our drug to compete against Avastin (Genentech/Roche)
and the FDA approved kinase inhibitors, because doctors and patients will have
significant experience using these medicines. In addition, an oral medication
may be considerably less expensive for patients than a biologic medication,
providing a competitive advantage to companies that market such
products.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
market for eye disease products is also very competitive. Novartis and
Genentech/Roche are collaborating on the commercialization and further
development of a VEGF antibody fragment, ranibizumab (Lucentis<SUP>&#174;</SUP>), for
the treatment of age-related macular degeneration (wet AMD) and other eye
indications that was approved by the FDA in June 2006. Many other companies are
working on the development of product candidates for the potential treatment of
wet AMD and DME that act by blocking VEGF, VEGF receptors, and through the use
of small interfering ribonucleic acids (siRNAs) that modulate gene expression.
In addition, ophthalmologists are using off-label a third-party reformatted
version of Genentech/Roche&#146;s approved VEGF antagonist, Avastin<SUP>&#174;</SUP>, with
success for the treatment of wet AMD. The National Eye Institute is conducting a
Phase 3 trial comparing Lucentis (Genentech/Roche) to Avastin (Genentech/Roche)
in the treatment of wet AMD. The marketing approval of Lucentis
(Genentech/Roche) and the potential off-label use of Avastin (Genentech/Roche)
make it more difficult for us to enroll patients in our clinical trials and
successfully develop VEGF Trap-Eye. Even if VEGF Trap-Eye is ever approved for
sale for the treatment of eye diseases, it may be difficult for our drug to
compete against Lucentis (Genentech/Roche), because doctors and patients will
have significant experience using this medicine. Moreover, the relatively low
cost of therapy with Avastin (Genentech/Roche) in patients with wet AMD presents
a further competitive challenge in this indication.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
availability of highly effective FDA approved TNF-antagonists such as
Enbrel<SUP>&#174;</SUP> (Immunex), Remicade<SUP>&#174;</SUP> (Centocor), and
Humira<SUP>&#174;</SUP> (Abbott Laboratories), and the IL-1 receptor antagonist
Kineret<SUP>&#174;</SUP> (Amgen), and other marketed therapies makes it more
difficult to successfully develop and commercialize ARCALYST<SUP>&#174;</SUP>
(rilonacept). This is one of the reasons we discontinued the development of
ARCALYST in adult rheumatoid arthritis. In addition, even if ARCALYST is ever
approved for sale in indications where TNF-antagonists are approved, it will be
difficult for our drug to compete against these FDA approved TNF-antagonists
because doctors and patients will have significant experience using these
effective medicines. Moreover, in such indications these approved therapeutics
may offer competitive advantages over ARCALYST, such as requiring fewer
injections.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There are
both small molecules and antibodies in development by other companies that are
designed to block the synthesis of interleukin-1 or inhibit the signaling of
interleukin-1. For example, Eli Lilly, Xoma, and Novartis are each developing
antibodies to interleukin-1 and Amgen is developing an antibody to the
interleukin-1 receptor. Novartis has filed applications in the U.S. and Europe
seeking regulatory approval of its IL-1 antibody in CAPS. Novartis is also
developing its IL-1 antibody in gout and other inflammatory diseases. Novartis
has stated that its IL-1 antibody demonstrated long-lasting clinical remission
in patients with CAPS and that its clinical candidate could develop into a major
therapeutic advance in the treatment of CAPS. Novartis&#146; IL-1 antibody and these
other drug candidates could offer competitive advantages over ARCALYST. The
successful development of these competing molecules could impair our ability to
successfully commercialize ARCALYST.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We have
plans to develop ARCALYST for the treatment of certain gout indications.
Currently, inexpensive, oral therapies such as analgesics and other
non-steroidal anti-inflammatory drugs are used as the standard of care to treat
the symptoms of these gout diseases. These established, inexpensive, orally
delivered drugs may make it difficult for us to successfully commercialize
ARCALYST in these diseases.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>40</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>The successful commercialization
of ARCALYST</FONT></I></B><B><FONT face=serif size=2><SUP>&#174;</SUP></FONT></B>
<B><I><FONT face=serif size=2>(rilonacept) and our product candidates will
depend on obtaining coverage and reimbursement for use of these products from
third-party payers and these payers may not agree to cover or reimburse for use
of our products.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
product candidates, if commercialized, may be significantly more expensive than
traditional drug treatments. For example, we have announced plans to initiate a
Phase 3 program studying the use of ARCALYST for the treatment of certain gout
indications. Patients suffering from these gout indications are currently
treated with inexpensive therapies, including non-steroidal anti-inflammatory
drugs. These existing treatment options are likely to be considerably less
expensive and may be preferable to a biologic medication for some patients. Our
future revenues and profitability will be adversely affected if United States
and foreign governmental, private third-party insurers and payers, and other
third-party payers, including Medicare and Medicaid, do not agree to defray or
reimburse the cost of our products to the patients. If these entities refuse to
provide coverage and reimbursement with respect to our products or provide an
insufficient level of coverage and reimbursement, our products may be too costly
for many patients to afford them, and physicians may not prescribe them. Many
third-party payers cover only selected drugs, making drugs that are not
preferred by such payer more expensive for patients, and require prior
authorization or failure on another type of treatment before covering a
particular drug. Payers may especially impose these obstacles to coverage on
higher-priced drugs, as our product candidates are likely to be.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We market
and sell ARCALYST in the United States for the treatment of a group of rare
genetic disorders called CAPS. There may be too few patients with CAPS to
profitably commercialize ARCALYST. Physicians may not prescribe ARCALYST, and
CAPS patients may not be able to afford ARCALYST, if third party payers do not
agree to reimburse the cost of ARCALYST therapy and this would adversely affect
our ability to commercialize ARCALYST profitably.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition to potential restrictions on coverage, the amount of reimbursement for
our products may also reduce our profitability. In the United States, there have
been, and we expect will continue to be, actions and proposals to control and
reduce healthcare costs. Government and other third-party payers are challenging
the prices charged for healthcare products and increasingly limiting, and
attempting to limit, both coverage and level of reimbursement for prescription
drugs.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Since
ARCALYST and our product candidates in clinical development, will likely be too
expensive for most patients to afford without health insurance coverage, if our
products are unable to obtain adequate coverage and reimbursement by third-party
payers our ability to successfully commercialize our product candidates may be
adversely impacted. Any limitation on the use of our products or any decrease in
the price of our products will have a material adverse effect on our ability to
achieve profitability.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
certain foreign countries, pricing, coverage, and level of reimbursement of
prescription drugs are subject to governmental control, and we may be unable to
negotiate coverage, pricing, and reimbursement on terms that are favorable to
us. In some foreign countries, the proposed pricing for a drug must be approved
before it may be lawfully marketed. The requirements governing drug pricing vary
widely from country to country. For example, the European Union provides options
for its member states to restrict the range of medicinal products for which
their national health insurance systems provide reimbursement and to control the
prices of medicinal products for human use. A member state may approve a
specific price for the medicinal product or it may instead adopt a system of
direct or indirect controls on the profitability of the company placing the
medicinal product on the market. Our results of operations may suffer if we are
unable to market our products in foreign countries or if coverage and
reimbursement for our products in foreign countries is limited.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risk Related to
Employees</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>We are dependent on our key
personnel and if we cannot recruit and retain leaders in our research,
development, manufacturing, and commercial organizations, our business will be
harmed.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We are
highly dependent on certain of our executive officers. If we are not able to
retain any of these persons or our Chairman, our business may suffer. In
particular, we depend on the services of P. Roy Vagelos, M.D., the Chairman of
our board of directors, Leonard Schleifer, M.D., Ph.D., our President and Chief
Executive Officer, George D. Yancopoulos, M.D., Ph.D., our Executive Vice
President, Chief Scientific Officer and President, Regeneron Research
Laboratories, and Neil Stahl, Ph.D., our Senior Vice President, Research and
Development Sciences. There is intense competition in the biotechnology industry
for qualified scientists and managerial personnel in the development,
manufacture, and commercialization of drugs. We may not be able to continue to
attract and retain the qualified personnel necessary for developing our
business.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>41</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>Our move to new facilities in
mid-2009 could lead to disruptions in our business
operations.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>We plan
to move most of our laboratories and headquarters to new facilities in mid-2009.
There is a risk that this physical move could lead to damage to equipment or
other business assets or the loss of important data, or that we could encounter
problems with our new facilities, which could disrupt or delay our business
operations.</FONT></P>
<P align=justify><B><FONT face=serif size=2>Risks Related to Our Common
Stock</FONT></B></P>
<P align=justify><B><I><FONT face=serif size=2>Our stock price is extremely
volatile.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>There has
been significant volatility in our stock price and generally in the market
prices of biotechnology companies&#146; securities. Various factors and events may
have a significant impact on the market price of our Common Stock. These factors
include, by way of example:</FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify">
  <LI><FONT face=serif size=2>progress, delays, or adverse results in clinical
  trials;</FONT>
  <LI><FONT face=serif size=2>announcement of technological innovations or
  product candidates by us or competitors;</FONT>
  <LI><FONT face=serif size=2>fluctuations in our operating results;</FONT>
  <LI><FONT face=serif size=2>third party claims that our products or
  technologies infringe their party patents;</FONT>
  <LI><FONT face=serif size=2>public concern as to the safety or effectiveness
  of ARCALYST<SUP>&#174;</SUP> (rilonacept) or any of our product candidates;</FONT>
  <LI><FONT face=serif size=2>developments in our relationship with
  collaborative partners;</FONT>
  <LI><FONT face=serif size=2>developments in the biotechnology industry or in
  government regulation of healthcare;</FONT>
  <LI><FONT face=serif size=2>large sales of our common stock by our executive
  officers, directors, or significant shareholders;</FONT>
  <LI><FONT face=serif size=2>arrivals and departures of key personnel;
  and</FONT>
  <LI><FONT face=serif size=2>general market conditions.</FONT></LI></UL>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>The
trading price of our Common Stock has been, and could continue to be, subject to
wide fluctuations in response to these and other factors, including the sale or
attempted sale of a large amount of our Common Stock in the market. Broad market
fluctuations may also adversely affect the market price of our Common
Stock.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>Future sales of our Common Stock
by our significant shareholders or us may depress our stock price and impair our
ability to raise funds in new share offerings.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>A small
number of our shareholders beneficially own a substantial amount of our Common
Stock. As of April 14, 2009, our five largest shareholders plus Leonard S.
Schleifer, M.D. Ph.D., our Chief Executive Officer, beneficially owned 52.5% of
our outstanding shares of Common Stock, assuming, in the case of our Chief
Executive Officer, the conversion of his Class A Stock into Common Stock and the
exercise of all options held by him which are exercisable within 60 days of
April 14, 2009. As of April 14, 2009, sanofi-aventis beneficially owned
14,799,552 shares of Common Stock, representing approximately 19.0% of the
shares of Common Stock then outstanding. Under our investor agreement with
sanofi-aventis, sanofi-aventis may not sell these shares until December 20, 2012
except under limited circumstances and subject to earlier termination of these
restrictions upon the occurrence of certain events. Notwithstanding these
restrictions, if sanofi-aventis, or our other significant shareholders or we,
sell substantial amounts of our Common Stock in the public market, or the
perception that such sales may occur exists, the market price of our Common
Stock could fall. Sales of Common Stock by our significant shareholders,
including sanofi-aventis, also might make it more difficult for us to raise
funds by selling equity or equity-related securities in the future at a time and
price that we deem appropriate.</FONT></P>
<P align=center><FONT face=serif></FONT><FONT face=serif size=2>42</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify><B><I><FONT face=serif size=2>Our existing shareholders may be
able to exert significant influence over matters requiring shareholder
approval.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Holders
of Class A Stock, who are generally the shareholders who purchased their stock
from us before our initial public offering, are entitled to ten votes per share,
while holders of Common Stock are entitled to one vote per share. As of April
14, 2009, holders of Class A Stock held 22.4% of the combined voting power of
all shares of Common Stock and Class A Stock then outstanding, plus any voting
power associated with any shares of Common Stock beneficially owned by such
Class A Stock holders. These shareholders, if acting together, would be in a
position to significantly influence the election of our directors and to effect
or prevent certain corporate transactions that require majority or supermajority
approval of the combined classes, including mergers and other business
combinations. This may result in us taking corporate actions that you may not
consider to be in your best interest and may affect the price of our Common
Stock. As of April 14, 2009:</FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify">
  <LI><FONT face=serif size=2>our current executive officers and directors
  beneficially owned 13.3% of our outstanding shares of Common Stock, assuming
  conversion of their Class A Stock into Common Stock and the exercise of all
  options held by such persons which are exercisable within 60 days of April 14,
  2009, and 28.2% of the combined voting power of our outstanding shares of
  Common Stock and Class A Stock, assuming the exercise of all options held by
  such persons which are exercisable within 60 days of April 14, 2009;
  and<BR>&nbsp;</FONT>
  <LI><FONT face=serif size=2>our five largest shareholders plus Leonard S.
  Schleifer, M.D., Ph.D., our Chief Executive Officer, beneficially owned 52.5%
  of our outstanding shares of Common Stock, assuming, in the case of our Chief
  Executive Officer, the conversion of his Class A Stock into Common Stock and
  the exercise of all options held by him which are exercisable within 60 days
  of April 14, 2009. In addition, these six shareholders held 57.2% of the
  combined voting power of our outstanding shares of Common Stock and Class A
  Stock, assuming the exercise of all options held by our Chief Executive
  Officer which are exercisable within 60 days of April 14, 2009.</FONT></LI></UL>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Pursuant to an investor agreement,
sanofi-aventis has agreed to vote its shares, at sanofi-aventis&#146; election,
either as recommended by our board of directors or proportionally with the votes
cast by our other shareholders, except with respect to certain change of control
transactions, liquidation or dissolution, stock issuances equal to or exceeding
10% of the then outstanding shares or voting rights of Common Stock and Class A
Stock, and new equity compensation plans or amendments if not materially
consistent with our historical equity compensation practices.</FONT></P>
<P align=justify><B><I><FONT face=serif size=2>The anti-takeover effects of
provisions of our charter, by-laws, and of New York corporate law and the
contractual &#147;standstill&#148; provisions in our investor agreement with
sanofi-aventis, could deter, delay, or prevent an acquisition or other &#147;change
in control&#148; of us and could adversely affect the price of our Common
Stock.</FONT></I></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Our
amended and restated certificate of incorporation, our by-laws and the New York
Business Corporation Law contain various provisions that could have the effect
of delaying or preventing a change in control of our company or our management
that shareholders may consider favorable or beneficial. Some of these provisions
could discourage proxy contests and make it more difficult for you and other
shareholders to elect directors and take other corporate actions. These
provisions could also limit the price that investors might be willing to pay in
the future for shares of our Common Stock. These provisions include:</FONT></P>
<UL style="FONT-SIZE: 10pt; TEXT-ALIGN: justify">
  <LI><FONT face=serif size=2>authorization to issue &#147;blank check&#148; preferred
  stock, which is preferred stock that can be created and issued by the board of
  directors without prior shareholder approval, with rights senior to those of
  our common shareholders;</FONT>
  <LI><FONT face=serif size=2>a staggered board of directors, so that it would
  take three successive annual meetings to replace all of our directors;</FONT>
  <LI><FONT face=serif size=2>a requirement that removal of directors may only
  be effected for cause and only upon the affirmative vote of at least eighty
  percent (80%) of the outstanding shares entitled to vote for directors, as
  well as a requirement that any vacancy on the board of directors may be filled
  only by the remaining directors;</FONT>
  <LI><FONT face=serif size=2>any action required or permitted to be taken at
  any meeting of shareholders may be taken without a meeting, only if, prior to
  such action, all of our shareholders consent, the effect of which is to
  require that shareholder action may only be taken at a duly convened
  meeting;</FONT>
  <LI><FONT face=serif size=2>any shareholder seeking to bring business before
  an annual meeting of shareholders must provide timely notice of this intention
  in writing and meet various other requirements; and</FONT>
  <LI><FONT face=serif size=2>under the New York Business Corporation Law, in
  addition to certain restrictions which may apply to &#147;business combinations&#148;
  involving the Company and an &#147;interested shareholder&#148;, a plan of merger or
  consolidation of the Company must be approved by two-thirds of the votes of
  all outstanding shares entitled to vote thereon. See the risk factor
  immediately above captioned</FONT> <I><FONT face=serif size=2>&#147;Our existing
  shareholders may be able to exert significant influence over matters requiring
  shareholder approval.&#148;</FONT></I><FONT face=serif size=2></FONT></LI></UL>
<P align=center><FONT face=serif size=2>43</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>Until the
later of the fifth anniversaries of the expiration or earlier termination of our
antibody collaboration agreements with sanofi-aventis or our aflibercept
collaboration with sanofi-aventis, sanofi-aventis will be bound by certain
"standstill" provisions, which contractually prohibit sanofi-aventis from
acquiring more than certain specified percentages of our Class A Stock and
Common Stock (taken together) or otherwise seeking to obtain control of the
Company.</FONT></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=serif size=2>In
addition, we have a Change in Control Severance Plan and our Chief Executive
Officer has an employment agreement that provides severance benefits in the
event our officers are terminated as a result of a change in control of the
Company. Many of our stock options issued under our Amended and Restated 2000
Long-Term Incentive Plan may become fully vested in connection with a &#147;change in
control&#148; of our company, as defined in the plan.</FONT></P>
<P align=justify><B><FONT face=serif size=2>ITEM 6. EXHIBITS</FONT></B></P>
<P align=justify><FONT face=serif size=2><FONT size=3>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>(a)</FONT><FONT face=serif size=2></FONT> <FONT face=serif size=2>Exhibits</FONT></P>
<TABLE style="FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><B><FONT face=serif size=2></FONT></B></TD>
    <TD noWrap align=left width="3%"><STRONG>Exhibit</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=left width="91%" colSpan=2></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"><B><FONT face=serif size=2>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><STRONG>Number</STRONG></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%" colSpan=4><B><FONT face=serif size=2>Description</FONT></B></TD>
    <TD noWrap align=left width="90%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"><FONT face=serif size=2>10.1</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap align=right width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=top align=left width="91%" colSpan=2>
      <P align=justify><FONT face=serif size=2>Form of option agreement and
      related notice of grant for use in connection with the grant of time based
      vesting stock options to the Registrant's non-employee directors and
      executive officers.</FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"></TD>
    <TD vAlign=top noWrap align=center width="1%">&nbsp;</TD>
    <TD vAlign=top align=left width="91%" colSpan=2><FONT face=serif size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"><FONT face=serif size=2>10.2</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top align=left width="91%" colSpan=2>
      <P align=justify><FONT face=serif size=2>Form of option agreement and
      related notice of grant for use in connection with the grant of
      performance based vesting stock options to the Registrant's executive
      officers.</FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top align=left width="91%" colSpan=2><FONT face=serif size=2>&nbsp;</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%" ></TD>
    <TD vAlign=top noWrap align=left width="3%" >10.3</TD>
    <TD vAlign=top noWrap align=center width="1%" ></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD>
    <TD vAlign=top noWrap align=right width="1%" >-</TD>
    <TD vAlign=top noWrap align=center width="1%" ></TD>
    <TD vAlign=top align=left width="91%"  colSpan=2>Third
      Amendment to lease, by and between BMR-Landmark at Eastview&nbsp; LLC and
      Regeneron Pharmaceuticals, Inc., entered into as of April 29, 2009.</TD></TR>
  <TR>
    <TD noWrap align=left width="1%" ></TD>
    <TD vAlign=top noWrap align=left width="3%" ></TD>
    <TD vAlign=top noWrap align=center width="1%" ></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD>
    <TD vAlign=top noWrap align=right width="1%" ></TD>
    <TD vAlign=top noWrap align=center width="1%" ></TD>
    <TD vAlign=top align=left width="91%"  colSpan=2>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"><FONT face=serif size=2>31.1</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top align=left width="91%" colSpan=2>
      <P align=justify><FONT face=serif size=2>Certification of CEO pursuant to
      Rule 13a-14(a) under the Securities Exchange Act of 1934.</FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top align=left width="91%" colSpan=2><FONT face=serif size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"><FONT face=serif size=2>31.2</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top align=left width="91%" colSpan=2>
      <P align=justify><FONT size=2>Certification of CFO pursuant to Rule
      13a-14(a) under the Securities Exchange Act of 1934.</FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top align=left width="91%" colSpan=2><FONT face=serif size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="3%"><FONT face=serif size=2>32</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%"></TD>
    <TD vAlign=top noWrap align=right width="1%"><FONT face=serif size=2>-</FONT></TD>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=left width="91%" colSpan=2>
      <P align=justify><FONT face=serif size=2>Certification of CEO and CFO
      pursuant to 18 U.S.C. Section 1350.</FONT></P></TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>44</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<PAGE>
<P align=center><B><U><FONT face=serif size=2>SIGNATURE</FONT></U></B></P>
<P align=justify><FONT face=serif size=2>Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2>
      <P align=justify><FONT face=serif size=2>Regeneron Pharmaceuticals,
      Inc.</FONT></P></TD></TR>
  <TR>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face=serif size=2>Date: April 30,
      2009</FONT></TD>
    <TD noWrap align=left width="1%">
      <P><FONT face=serif size=2>By:&nbsp;</FONT></P></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="49%"><P><FONT face=serif size=2>/s/</FONT> <FONT style="FONT-VARIANT: small-caps" face=serif size=2>Murray A.
      Goldberg</FONT></P></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>Murray
      A. Goldberg</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>Senior
      Vice President, Finance &amp; Administration,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>Chief
      Financial Officer, Treasurer, and</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>Assistant Secretary</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>(Principal Financial Officer and</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=2><FONT face=serif size=2>Duly
      Authorized Officer)</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face=serif size=2>45</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
